prazosin has been researched along with Cardiac Failure in 307 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prazosin is an orally active post-synaptic selective alpha 1-adrenoreceptor antagonist that has been widely used in treating hypertension and congestive heart failure (CHF)." | 10.15 | Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. ( Brogden, RN; Kellerman, D; Romankiewicz, JA; Stanaszek, WF, 1983) |
| "To determine the acute haemodynamic response of a single dose co-administration of ibopamine plus prazosin in patients with congestive heart failure." | 9.08 | Evaluation of ibopamine plus prazosin in congestive heart failure. ( Mitha, AS; Naidoo, DP; Rocke, A, 1998) |
| "To better define the effects of long-term vasodilator therapy on exercise performance in chronic congestive heart failure, we compared placebo with prazosin and with the combination of hydralazine and isosorbide dinitrate (Hyd-Iso) in 642 men over a 5-year period in V-HeFT I." | 9.07 | Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cobb, FR; Cohn, JN; Johnson, G; Tristani, F; Ziesche, S, 1993) |
| "Despite better survival in patients randomized to hydralazine plus isosorbide dinitrate compared with placebo and better survival in patients randomized to enalapril compared with hydralazine plus isosorbide dinitrate, no significant differences between the treatment groups were apparent in the incidence of hospitalization or time to first hospitalization for congestive heart failure, for cardiac reasons other than congestive heart failure, or for other causes." | 9.07 | Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Cremo, R; Henrick, A; Johnson, G; Loeb, HS; Smith, R; Wilson, J, 1993) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 9.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 9.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "Fifty patients with congestive heart failure received, by infusion, 15 ml/kg body weight water load, and systemic hemodynamic, renal function, and neurohumoral parameters values were measured before, 2 days, and 1 month after randomly allocating patients to prazosin or captopril therapy." | 9.06 | Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. ( Bichet, D; Chatterjee, K; Kortas, C; Manzini, C; Mettauer, B; Rouleau, JL; Tremblay, G, 1986) |
| "A double blind cross over study was performed to compare the long term hormonal, haemodynamic, and clinical responses to specific inhibition of the renin-angiotensin-aldosterone system (captopril) and of the alpha 1 adrenoceptors of the sympathetic system (prazosin) both at rest and during upright exercise in patients with chronic heart failure." | 9.06 | Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. ( Bayliss, J; Canepa-Anson, R; Norell, MS; Poole-Wilson, P; Sutton, G, 1986) |
| "The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study." | 9.06 | Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986) |
| "The acute hemodynamic effects and long-term therapeutic actions of low doses of the oral angiotensin-converting enzyme (ACE) inhibitor captopril (CPT) were evaluated in 18 patients with severe chronic congestive heart failure (CHF)." | 9.05 | Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. ( Coxon, R; Sharpe, DN, 1982) |
| "The beneficial effects of acute prazosin therapy in patients with congestive heart failure (CHF) have been well documented; however, its chronic efficacy over several months has not previously been evaluated in a placebo-controlled manner." | 9.05 | Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. ( Corbett, JR; Firth, BG; Gilmore, A; Markham, RV; Pettinger, WA, 1983) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 9.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure." | 9.05 | Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980) |
| "To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy." | 9.05 | Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981) |
| "Long-term treatment of congestive heart failure with prazosin is disputed." | 9.05 | [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985) |
| "In addition to standard treatment with digitalis and diuretics prazosin (20 mg/d) and placebo were given to 14 patients with chronic therapy-resistant cardiac failure mainly of stage III for periods of 6 weeks each." | 9.04 | [Effect of prazosin in therapy-resistant chronic cardiac failure (author's transl)]. ( Bussmann, WD; Kaltenbach, M; Lemke, R; Trompler, A, 1979) |
| "We report our hemodynamic, clinical, and neuroendocrine observations during long-term (8 weeks) prazosin (PZN) administration to assess the efficacy of this agent in the long-term therapy of congestive heart failure (CHF) and to emphasize the potential role of neuroendocrine mechanisms in the determination of overall drug effect." | 8.76 | Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. ( Braunwald, E; Colucci, WS; Williams, GH, 1981) |
| "Prazosin, an orally active alpha-1 selective adrenergic antagonist, has been of value in treating patients with hypertension and congestive heart failure." | 8.76 | Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. ( Colucci, WS, 1982) |
| "The cardiocirculatory actions of prazosin (PZN) orally were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise, and symptoms in patients with advanced long-standing congestive heart failure (CHF)." | 8.76 | Management of refractory congestive heart failure with prazosin. ( Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1981) |
| "To determine the hemodynamic effects of a new alpha-1 blocker, terazosin, in congestive heart failure, 10 patients with this condition underwent hemodynamic testing at rest." | 7.68 | Hemodynamic effects of terazosin in congestive heart failure. ( Liu, Z; Lu, Z; Wang, D; Yang, D; Zhu, J, 1993) |
| "A retrospective study was undertaken to evaluate the impact of captopril on intrahospital mortality and the duration of hospitalization in Nigerians with congestive heart failure." | 7.68 | The influence of captopril on intrahospital mortality and duration of hospitalization in Nigerians with congestive heart failure. ( Ajayi, AA; Akintomide, AO; Osodi, OO, 1992) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 7.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "Although arginine vasopressin (AVP) is elevated in heart failure, inhibition of the vasopressinergic V1-receptor produces minimal changes in blood pressure." | 7.68 | Attenuation of pressor responses to arginine vasopressin in right-sided congestive heart failure. ( Imai, N; Liang, CS; Sladek, CD; Stone, CK, 1990) |
| "To determine the hemodynamic effects of a new alpha 1 blocker, terazosin, in congestive heart failure, six patients with this condition underwent hemodynamic testing (at rest and during exercise) before and after dosing." | 7.67 | The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. ( Huss, P; Leier, CV; Parrish, D; Patterson, SE; Unverferth, DV, 1986) |
| "Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were investigated." | 7.67 | [Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs]. ( Sonoki, H; Sugimoto, T; Tomaru, T; Uchida, Y, 1988) |
| "Central hemodynamic parameters were monitored by invasive procedures (pulmonary arterial catheterization), and prazosin kinetics following the administration of a single 5 mg dose were determined in 69 patients with subacute myocardial infarction, complicated by heart failure." | 7.67 | [Prazosin pharmacodynamics and pharmacokinetics in patients with myocardial infarct complicated by heart failure in the subacute period]. ( Gofman, AM; Ol'binskaia, LI; Petrosian, IuR, 1987) |
| "Short- and long-term hemodynamic and clinical responses to sequential therapy with prazosin (15 mg/day for 3 to 12 weeks) and captopril (75 to 300 mg/day for 2 to 15 weeks) were compared in 22 patients with severe chronic congestive heart failure." | 7.67 | Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "To determine the effects of the renin-angiotensin-aldosterone system on development of tolerance and fluid retention in patients with chronic congestive heart failure during long-term prazosin treatment, plasma renin concentration, aldosterone, norepinephrine and maximal exercise tolerance were measured during chronic therapy with digitalis and diuretics, to which prazosin, captopril or a combination of both drugs was added." | 7.67 | Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. ( Haeske, W; Kochsiek, K; Kraus, C; Kromer, EP; Riegger, GA, 1987) |
| "The cardiocirculatory actions of the oral vasodilator prazosin were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise, and symptoms in patients with advanced long-standing congestive heart failure." | 7.66 | Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin. ( Awan, NA; Beattie, JM; Evenson, ME; Mason, DT; Needham, KE, 1982) |
| "0 mg prazosin was given to 14 patients with congestive heart failure to assess its effect." | 7.66 | Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin. ( Hayashi, H; Ogasawara, B; Ogawa, K; Sassa, H, 1981) |
| "The oral angiotensin-converting enzyme inhibitor captopril (CPT) produces beneficial hemodynamic and clinical responses in patients with chronic congestive heart failure (CHF)." | 7.66 | Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Four studies were conducted in 36 patients with severe chronic heart failure to compare the central hemodynamic effects of captopril (CPT) to other vasodilator agents." | 7.66 | Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. ( Medina, N; Packer, M; Yushak, M, 1982) |
| "Eight patients, ranging in age from 20 to 61 years (48 +/- 11 years, mean +/- 1 SD), with chronic heart failure due to idiopathic congestive cardiomyopathy (5 cases), ischemic heart disease with healed anterior myocardial infarction (2 cases), and rheumatic heart disease with a Björk-Shiley mitral valve prosthesis (1 case), received longterm therapy with oral prazosin in increasing doses (mean final dose: 26 +/- 6 mg/day)." | 7.66 | [Long-term therapy with oral prazosin in chronic congestive heart failure: a clinical and echocardiographic evaluation (author's transl)]. ( Cesari, GP; Soro, A; Sparvieri, F, 1980) |
| "We evaluated the effects of long-term maintenance therapy with oral prazosin (6-20 mg, mean 14 +/- 2 mg/d) in 14 patients with congestive heart failure." | 7.66 | Long-term maintenance therapy with prazosin in congestive heart failure. ( Conti, CR; Iacona, M; Mehta, J; Miles, D, 1981) |
| "The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure." | 7.66 | Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980) |
| "To clarify the hemodynamic effects of prazosin in congestive heart failure, the changes of blood distribution were examined radiocardiographically in 9 patients." | 7.66 | Non-invasive radiocardiographic assessment of the effects of prazosin in congestive heart failure. ( Kawai, C; Kawashita, K; Nakajima, H; Yoshida, A; Yui, Y, 1982) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 7.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "Thirteen patients with advanced congestive heart failure (CHF) were treated with prazosin." | 7.66 | Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. ( Ball, RM; Feldman, RC; Harrison, DC; Jaillon, P; Kates, RE; Winchester, MA, 1981) |
| "To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months." | 7.66 | Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981) |
| "The hemodynamic effects of oral doses of prazosin and hydralazine were studied in the same group of patients with chronic congestive heart failure." | 7.66 | Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. ( Elkayam, U; Frishman, W; LeJemtel, T; Mathur, M; Sonnenblick, EH; Strom, J, 1981) |
| "In 10 patients with severe chronic congestive heart failure, changes in hemodynamic and cardiac performance at rest and during exercise were evaluated following short-term oral prazosin therapy." | 7.66 | Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure. ( Chatterjee, K; Parmley, WW; Ports, TA; Rubin, SA, 1981) |
| "Reviewed here are the data from 34 patients given prazosin for chronic intractable heart failure." | 7.66 | Prazosin and congestive heart failure: short- and long-term therapy. ( Burgess, JH; Rouleau, JL; Warnica, JW, 1981) |
| "The cardiocirculatory actions on the oral vasodilator prazosin were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise and symptoms in patients with advanced long-standing congestive heart failure." | 7.66 | Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective. ( Amsterdam, EE; Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1981) |
| "Central hemodynamic variables and regional blood flow and vascular resistances were ascertained in patients with severe congestive heart failure before and after the oral administration of prazosin hydrochloride or hydralazine." | 7.66 | Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. ( Bay, WH; Desch, CE; Leier, CV; Magorien, RD; Triffon, DW; Unverferth, DV, 1981) |
| "The effect of prazosin in congestive heart failure was assessed in 10 patients (age 39--69) years) with ischemic heart disease or cardiomyopathy in functional class II-IV (NYHA)." | 7.66 | Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure. ( Lund-Johansen, P; Ohm, OJ; von der Lippe, G, 1981) |
| "Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure." | 7.66 | Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981) |
| "To study the effect of prazosin therapy on left ventricular function in patients with chronic stable heart failure, first pass radionuclide angiography at rest and during exercise was performed in 15 patients before the administration of prazosin and after seven to 12 weeks of prazosin therapy." | 7.66 | Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. ( Cannon, PJ; Escala, E; Goldman, SA; Johnson, LL; Weiss, MB, 1980) |
| "The pharmacokinetics of prazosin (Minipress) were studied in nine patients with NYHA Class 3 or 4 congestive heart failure and in five healthy controls." | 7.66 | Altered prazosin pharmacokinetics in congestive heart failure. ( Arnold, S; Baughman, RA; Benet, LZ; Chatterjee, K; Lin, ET; Williams, RL, 1980) |
| "Prazosin improves hemodynamics promptly in patients with congestive heart failure (CHF), but tolerance to repeated doses may develop rapidly." | 7.66 | Effect of prazosin on renal function in congestive heart failure. ( Cohn, JN; Franciosa, JA; Pierpont, GL, 1980) |
| "To ascertain whether increased sympathetic nervous system activity may contribute to the attenuation of prazosin's effect on congestive heart failure, we measured plasma norepinephrine levels in 10 patients with severe heart failure before and after chronic prazosin therapy." | 7.66 | Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. ( Braunwald, E; Colucci, WS; Williams, GH, 1980) |
| " To determine whether this vasodilator elicits a positive inotropic response in the failing human ventricle, hydralazine, 75 or 100 mg, was administered orally to 14 patients with left ventricular dysfunction and congestive heart failure; the results were compared with those of first-dose prazosin at 5 and 10 mg." | 7.66 | Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. ( Boudoulas, H; Desch, CE; Leier, CV; Lewis, RP; Magorien, RD; Triffon, DW; Unverferth, DV, 1980) |
| "In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months." | 7.66 | [Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980) |
| "The kinetics of oral prazosin was studied in 10 healthy normal subjects (NS) and in 9 patients with congestive heart failure (CHF)." | 7.66 | Influence of congestive heart failure on prazosin kinetics. ( Ball, R; Blaschke, T; Harrison, D; Jaillon, P; Kates, R; Rubin, P; Yee, YG, 1979) |
| "To compare the hemodynamic effects of prazosin and nitroprusside in patients with severe congestive heart failure, nine patients with heart failure refractory to conventional therapy received oral prazosin and intravenous nitroprusside administered so as to produce a similar decrease in left ventricular filling pressure in each patient." | 7.66 | Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin. ( Gorlin, R; Herman, MV; Meller, J; Packer, M, 1979) |
| "A case of angina pectoris worsened by prazosin is presented." | 7.66 | Exacerbation of angina pectoris by prazosin. ( Charness, ME; Fishman, JA; Robertson, D, 1979) |
| "The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure." | 7.66 | Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979) |
| "The hemodynamic effects of the new oral vasocilator prazosin were evaluated in 11 patients with congestive failure following myocardial infarction." | 7.66 | Use of oral prazosin hydrochloride in congestive failure following acute myocardial infarction. ( Coma-Canella, I; Jadraque, LM; Lombera, F; Lopez-Sendon, J, 1979) |
| "Prazosin was administered orally at a maximal dose of 2 mg every 6 hours to 4 patients with congestive heart failure (CHF) who had not received either digitalis or diuretics for 72 hours before therapy." | 7.66 | Serial hemodynamic studies during the treatment of congestive heart failure with isolated low-dose oral prazosin therapy. ( Benchimol, A; Desser, KB; Reyns, PR; Romney, D, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 7.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 7.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "We compared cardiocirculatory actions of nitroprusside (NP) to prazosin (PZ) in eleven chronic coronary patients with refractory congestive heart failure." | 7.66 | Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. ( Awan, NA; Mason, DT; Miller, RR, 1978) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 7.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 7.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "To elucidate the hemodynamic effects of prazosin, an antihypertensive agent, in congestive heart failure, we studied 10 patients with ischemic cardiomyopathy and severe ventricular dysfunction." | 7.65 | Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. ( Awan, NA; Mason, DT; Maxwell, KS; Miller, RR, 1977) |
| "The dobutamine-induced increase in cardiac index remained virtually unchanged." | 6.67 | Preliminary evidence for the mechanism underlying the development of tolerance to prazosin in congestive heart failure: the alpha-agonistic properties of dobutamine unmasked by prazosin treatment. ( Giesen, G; Kersting, F; Kupp, M, 1993) |
| "Prazosin pre-treatment did not alter any of the renal responses to frusemide treatment (mean dose 85 +/- 14 mg)." | 6.67 | Renal effects of low dose prazosin in patients with congestive heart failure. ( Choy, AM; Lang, CC; Rahman, AR; Struthers, AD, 1993) |
| "Treatment with hydralazine-nitrate produced a 28% reduction in mortality compared with that in patients receiving placebo (95% confidence interval, 3% to 46%), whereas prazosin exerted no apparent beneficial effect." | 6.66 | Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1987) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 6.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Prazosin is an orally active post-synaptic selective alpha 1-adrenoreceptor antagonist that has been widely used in treating hypertension and congestive heart failure (CHF)." | 6.15 | Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. ( Brogden, RN; Kellerman, D; Romankiewicz, JA; Stanaszek, WF, 1983) |
| "The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management." | 6.15 | Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. ( Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR, 1981) |
| "Ten patients with congestive heart failure (class III and IV) underwent hemodynamic evaluation before and after a 5-mg oral dose of terazosin." | 5.28 | Rest and exercise cardiovascular effects of terazosin in congestive heart failure. ( Boudoulas, H; Leier, CV; Magorien, RD; Sinnathamby, S; Unverferth, DV, 1990) |
| "Therapy to decrease the load in congestive heart failure is now classified as acute and chronic vasodilator therapy." | 5.27 | Effect of prostacyclin and prazosin in the treatment of congestive heart failure; with special reference to the sympathetic nervous system. ( Kawai, C; Nakajima, H; Sakurai, T; Yui, Y, 1984) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Twelve patients with congestive heart failure were monitored with invasive and noninvasive techniques to evaluate the effect of vasodilator treatment." | 5.26 | Effects of red rest and prazosin in congestive heart failure. ( Forfang, K; Ihlen, H; Kjekshus, J; Storstein, O; Thaulow, E, 1982) |
| "We tested the hypothesis that concurrent inhibition of the renin angiotensin system by enalapril (5 mg) and the sympathetic nervous system by alpha 1 adrenergic blockade (prazosin 1 mg) will be superior to enalapril alone in 17 patients with heart failure on standard therapy, in a single blind, placebo-controlled, randomized parallel group study for 4 weeks." | 5.08 | Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure. ( Ajayi, AA; Balogun, MO; Sofowora, GG, 1996) |
| "To determine the acute haemodynamic response of a single dose co-administration of ibopamine plus prazosin in patients with congestive heart failure." | 5.08 | Evaluation of ibopamine plus prazosin in congestive heart failure. ( Mitha, AS; Naidoo, DP; Rocke, A, 1998) |
| "To better define the effects of long-term vasodilator therapy on exercise performance in chronic congestive heart failure, we compared placebo with prazosin and with the combination of hydralazine and isosorbide dinitrate (Hyd-Iso) in 642 men over a 5-year period in V-HeFT I." | 5.07 | Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cobb, FR; Cohn, JN; Johnson, G; Tristani, F; Ziesche, S, 1993) |
| "Despite better survival in patients randomized to hydralazine plus isosorbide dinitrate compared with placebo and better survival in patients randomized to enalapril compared with hydralazine plus isosorbide dinitrate, no significant differences between the treatment groups were apparent in the incidence of hospitalization or time to first hospitalization for congestive heart failure, for cardiac reasons other than congestive heart failure, or for other causes." | 5.07 | Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Cremo, R; Henrick, A; Johnson, G; Loeb, HS; Smith, R; Wilson, J, 1993) |
| "The incidence of thromboembolism and stroke in class II or III congestive heart failure is not high and may not be significantly reduced with warfarin treatment." | 5.07 | Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Bhat, G; Carson, PE; Cohn, JN; Dunkman, WB; Farrell, L; Johnson, GR, 1993) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 5.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 5.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The effects of prazosin, clonidine, and indoramin on central and regional hemodynamic parameters and left ventricular performance were analyzed in a congestive heart failure population to compare the pharmacodynamic responses to different levels of alpha-adrenergic interruption in this condition." | 5.06 | Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure. ( Good, AP; Leier, CV; Unverferth, DV, 1988) |
| "The reduction of mortality in patients with chronic congestive heart failure treated with the vasodilator regimen hydralazine and isosorbide dinitrate compared to those treated with placebo or prazosin in the Veterans Administration Cooperative Study (V-HeFT) was examined in order to explore the possible mechanism of the favourable effect." | 5.06 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. ( Cohn, JN, 1988) |
| "Fifty patients with congestive heart failure received, by infusion, 15 ml/kg body weight water load, and systemic hemodynamic, renal function, and neurohumoral parameters values were measured before, 2 days, and 1 month after randomly allocating patients to prazosin or captopril therapy." | 5.06 | Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. ( Bichet, D; Chatterjee, K; Kortas, C; Manzini, C; Mettauer, B; Rouleau, JL; Tremblay, G, 1986) |
| "A double blind cross over study was performed to compare the long term hormonal, haemodynamic, and clinical responses to specific inhibition of the renin-angiotensin-aldosterone system (captopril) and of the alpha 1 adrenoceptors of the sympathetic system (prazosin) both at rest and during upright exercise in patients with chronic heart failure." | 5.06 | Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. ( Bayliss, J; Canepa-Anson, R; Norell, MS; Poole-Wilson, P; Sutton, G, 1986) |
| "To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day)." | 5.06 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1986) |
| "The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study." | 5.06 | Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986) |
| "The acute hemodynamic effects and long-term therapeutic actions of low doses of the oral angiotensin-converting enzyme (ACE) inhibitor captopril (CPT) were evaluated in 18 patients with severe chronic congestive heart failure (CHF)." | 5.05 | Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. ( Coxon, R; Sharpe, DN, 1982) |
| "The beneficial effects of acute prazosin therapy in patients with congestive heart failure (CHF) have been well documented; however, its chronic efficacy over several months has not previously been evaluated in a placebo-controlled manner." | 5.05 | Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. ( Corbett, JR; Firth, BG; Gilmore, A; Markham, RV; Pettinger, WA, 1983) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 5.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure." | 5.05 | Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980) |
| "To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy." | 5.05 | Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981) |
| "The acute haemodynamic effects of 40 mg isosorbide dinitrate (10 subjects), 4 mg prazosin (20 subjects) and 50 mg dihydralazine (8 subjects) were compared in 24 patients with the clinical picture of chronic therapy-resistant cardiac failure (NY Heart Association stages III-IV)." | 5.05 | [Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)]. ( Himmler, FC; Klein, G; Kutschera, I; Sauer, E; Schmidt, G; Wirtzfeld, A, 1980) |
| "Long-term treatment of congestive heart failure with prazosin is disputed." | 5.05 | [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985) |
| "In order to determine and compare the pharmacodynamic responses to single and multiple dose prazosin therapy in cardiac failure, 14 patients with severe low-output heart failure underwent central and regional hemodynamic measurements after random placement in one of two prazosin dosing schedules." | 5.04 | Development of pharmacodynamic tolerance to prozosin in congestive heart failure. ( Blanford, MF; Desch, CE; Leier, CV; Magorien, RD; Triffon, DW; Unverferth, DV, 1979) |
| "In addition to standard treatment with digitalis and diuretics prazosin (20 mg/d) and placebo were given to 14 patients with chronic therapy-resistant cardiac failure mainly of stage III for periods of 6 weeks each." | 5.04 | [Effect of prazosin in therapy-resistant chronic cardiac failure (author's transl)]. ( Bussmann, WD; Kaltenbach, M; Lemke, R; Trompler, A, 1979) |
| "We report our hemodynamic, clinical, and neuroendocrine observations during long-term (8 weeks) prazosin (PZN) administration to assess the efficacy of this agent in the long-term therapy of congestive heart failure (CHF) and to emphasize the potential role of neuroendocrine mechanisms in the determination of overall drug effect." | 4.76 | Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. ( Braunwald, E; Colucci, WS; Williams, GH, 1981) |
| "Prazosin, an orally active alpha-1 selective adrenergic antagonist, has been of value in treating patients with hypertension and congestive heart failure." | 4.76 | Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. ( Colucci, WS, 1982) |
| "The cardiocirculatory actions of prazosin (PZN) orally were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise, and symptoms in patients with advanced long-standing congestive heart failure (CHF)." | 4.76 | Management of refractory congestive heart failure with prazosin. ( Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1981) |
| "The present study sought to evaluate the effects of the afterload-reducing drugs captopril and prazosin on changes in antioxidants as well as oxidative stress in relation to hemodynamic function in congestive heart failure (CHF) subsequent to myocardial infarction (MI)." | 3.69 | Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. ( Khaper, N; Singal, PK, 1997) |
| "To determine the hemodynamic effects of a new alpha-1 blocker, terazosin, in congestive heart failure, 10 patients with this condition underwent hemodynamic testing at rest." | 3.68 | Hemodynamic effects of terazosin in congestive heart failure. ( Liu, Z; Lu, Z; Wang, D; Yang, D; Zhu, J, 1993) |
| "To investigate intrarenal hemodynamics and effects of alpha 1-adrenergic blockade on glomerular functions in congestive heart failure (CHF), micropuncture studies were performed before and after intravenous injection of terazosin (1 microgram/100 g body wt iv) in eight myocardial infarction (MI) and in nine sham-operated rats after intraperitoneal injection of Inactin (70 mg/kg)." | 3.68 | Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats. ( Frohlich, ED; Nishikimi, T; Uchino, K, 1992) |
| "A retrospective study was undertaken to evaluate the impact of captopril on intrahospital mortality and the duration of hospitalization in Nigerians with congestive heart failure." | 3.68 | The influence of captopril on intrahospital mortality and duration of hospitalization in Nigerians with congestive heart failure. ( Ajayi, AA; Akintomide, AO; Osodi, OO, 1992) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 3.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "Although arginine vasopressin (AVP) is elevated in heart failure, inhibition of the vasopressinergic V1-receptor produces minimal changes in blood pressure." | 3.68 | Attenuation of pressor responses to arginine vasopressin in right-sided congestive heart failure. ( Imai, N; Liang, CS; Sladek, CD; Stone, CK, 1990) |
| " A Veterans Administration (VA) cooperative study published in June 1986 showed that congestive heart failure (CHF) patients who had hydralazine and isosorbide added to their drug therapy had less mortality than patients given digoxin and diuretics with or without prazosin." | 3.68 | Impact of a drug-use review program intervention on prescribing after publication of a randomized clinical trial. ( Bjornson, DC; Daniels, CE; Litman, TJ; Rector, TS; Snowdon, DA; Wertheimer, AI, 1990) |
| "To determine the effects of vasodilator and inotropic therapy on hyponatremia in patients with severe heart failure, we measured serum sodium concentration before and after treatment with captopril (70 patients), hydralazine (42 patients), prazosin (22 patients), and amrinone (19 patients), while diuretic dosages were kept constant." | 3.67 | Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "By means of specific inhibitors of the renin-angiotensin system (captopril) and of the sympathetic nervous activity (prazosin) in dogs with congestive heart failure, and by using a specific antagonist of the pressor activity of arginine vasopressin in rats with heart failure, we studied the influence of these pressor hormone systems on peripheral vascular resistance and cardiac function." | 3.67 | Neurohumoral vasoconstrictor systems in heart failure. ( Riegger, AJ, 1985) |
| "The pharmacokinetics of terazosin have been assessed in human volunteers, hypertensive patients, a limited number of elderly volunteers, and a small number of patients with congestive heart failure." | 3.67 | Pharmacokinetics of terazosin. ( Sonders, RC, 1986) |
| "To determine the hemodynamic effects of a new alpha 1 blocker, terazosin, in congestive heart failure, six patients with this condition underwent hemodynamic testing (at rest and during exercise) before and after dosing." | 3.67 | The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. ( Huss, P; Leier, CV; Parrish, D; Patterson, SE; Unverferth, DV, 1986) |
| "Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were investigated." | 3.67 | [Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs]. ( Sonoki, H; Sugimoto, T; Tomaru, T; Uchida, Y, 1988) |
| " On this basis, functional and therapeutical regimen of regression of cardiac hypertrophy (prazosin, clonidine, nifedipine) are analyzed in concentric as well as in excentric hypertrophy in patients with arterial hypertension." | 3.67 | [Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects]. ( Strauer, BE, 1985) |
| "The purpose of the present study was to find out whether the beneficial effect of prazosin in congestive heart failure persists after 2 and 6 months of treatment and whether the clinical and haemodynamic data obtained correlate with the response to treatment." | 3.67 | [Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency]. ( Aumont, MC; Cohen-Solal, A; Gourgon, R; Le Pailleur, C; Motté, G; Vacheron, A, 1987) |
| "Arginine vasopressin is elevated in congestive heart failure." | 3.67 | Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. ( Hood, WB; Imai, N; Liang, CS; Sakamoto, S; Sladek, CD; Stone, CK, 1988) |
| "In order to select the optimal vasodilator for the treatment of patients with congestive heart failure (CHF), the acute effects of three vasodilators (isosorbide dinitrate (ISDN) 5 mg, nifedipine 10 mg, and prazosin 1 mg) on peripheral capacitance and resistance vessels (CV and RV) were evaluated by a newly devised radionuclear technique (Study 1)." | 3.67 | Radionuclear measurement of peripheral hemodynamics in selection of vasodilators for treatment of heart failure. ( Fujisue, R; Iwasaki, T; Ohyanagi, M; Todo, Y, 1988) |
| "Central hemodynamic parameters were monitored by invasive procedures (pulmonary arterial catheterization), and prazosin kinetics following the administration of a single 5 mg dose were determined in 69 patients with subacute myocardial infarction, complicated by heart failure." | 3.67 | [Prazosin pharmacodynamics and pharmacokinetics in patients with myocardial infarct complicated by heart failure in the subacute period]. ( Gofman, AM; Ol'binskaia, LI; Petrosian, IuR, 1987) |
| "Short- and long-term hemodynamic and clinical responses to sequential therapy with prazosin (15 mg/day for 3 to 12 weeks) and captopril (75 to 300 mg/day for 2 to 15 weeks) were compared in 22 patients with severe chronic congestive heart failure." | 3.67 | Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "To determine the effects of the renin-angiotensin-aldosterone system on development of tolerance and fluid retention in patients with chronic congestive heart failure during long-term prazosin treatment, plasma renin concentration, aldosterone, norepinephrine and maximal exercise tolerance were measured during chronic therapy with digitalis and diuretics, to which prazosin, captopril or a combination of both drugs was added." | 3.67 | Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. ( Haeske, W; Kochsiek, K; Kraus, C; Kromer, EP; Riegger, GA, 1987) |
| "Pharmacokinetic and haemodynamic studies with the alpha-1 adrenoceptor antagonist prazosin were made in 20 patients disabled by chronic ischaemic heart failure." | 3.66 | The pharmacokinetic, pharmacodynamic and haemodynamic effects of acute and chronic alpha-adrenoceptor blockade in chronic heart failure. ( Silke, B; Taylor, SH, 1981) |
| "The effects of long-term therapy with captopril (CPT) were studied in 11 patients with severe chronic congestive heart failure (CHF)." | 3.66 | Variable clinical response to long-term angiotensin inhibition in severe heart failure: demonstration of additive benefits of alpha-receptor blockade. ( Frishman, W; Kugler, J; LeJemtel, TH; Maskin, CS; Sonnenblick, EH, 1982) |
| "The cardiocirculatory actions of the oral vasodilator prazosin were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise, and symptoms in patients with advanced long-standing congestive heart failure." | 3.66 | Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin. ( Awan, NA; Beattie, JM; Evenson, ME; Mason, DT; Needham, KE, 1982) |
| "0 mg prazosin was given to 14 patients with congestive heart failure to assess its effect." | 3.66 | Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin. ( Hayashi, H; Ogasawara, B; Ogawa, K; Sassa, H, 1981) |
| "The oral angiotensin-converting enzyme inhibitor captopril (CPT) produces beneficial hemodynamic and clinical responses in patients with chronic congestive heart failure (CHF)." | 3.66 | Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Four studies were conducted in 36 patients with severe chronic heart failure to compare the central hemodynamic effects of captopril (CPT) to other vasodilator agents." | 3.66 | Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. ( Medina, N; Packer, M; Yushak, M, 1982) |
| "Eight patients, ranging in age from 20 to 61 years (48 +/- 11 years, mean +/- 1 SD), with chronic heart failure due to idiopathic congestive cardiomyopathy (5 cases), ischemic heart disease with healed anterior myocardial infarction (2 cases), and rheumatic heart disease with a Björk-Shiley mitral valve prosthesis (1 case), received longterm therapy with oral prazosin in increasing doses (mean final dose: 26 +/- 6 mg/day)." | 3.66 | [Long-term therapy with oral prazosin in chronic congestive heart failure: a clinical and echocardiographic evaluation (author's transl)]. ( Cesari, GP; Soro, A; Sparvieri, F, 1980) |
| "We evaluated the effects of long-term maintenance therapy with oral prazosin (6-20 mg, mean 14 +/- 2 mg/d) in 14 patients with congestive heart failure." | 3.66 | Long-term maintenance therapy with prazosin in congestive heart failure. ( Conti, CR; Iacona, M; Mehta, J; Miles, D, 1981) |
| "Prazosine was studied in the treatment of chronic heart failure in 17 patients." | 3.66 | [Immediate and long-term effects of prazosin on hemodynamics in chronic cardiac insufficiency]. ( Brunhes, G; Champoud, O; Cribier, A; Letac, B; Pasquis, P, 1982) |
| "Therapy with prazosin can improve the condition of patients with congestive heart failure due to its vasodilating action." | 3.66 | Noninvasive assessment of left ventricular wall stress in chronic congestive heart failure patients. ( Abdou, O; Chandy, F; Gopalaswamy, C; Gould, L, 1983) |
| "The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure." | 3.66 | Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980) |
| "To clarify the hemodynamic effects of prazosin in congestive heart failure, the changes of blood distribution were examined radiocardiographically in 9 patients." | 3.66 | Non-invasive radiocardiographic assessment of the effects of prazosin in congestive heart failure. ( Kawai, C; Kawashita, K; Nakajima, H; Yoshida, A; Yui, Y, 1982) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 3.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "Thirteen patients with advanced congestive heart failure (CHF) were treated with prazosin." | 3.66 | Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. ( Ball, RM; Feldman, RC; Harrison, DC; Jaillon, P; Kates, RE; Winchester, MA, 1981) |
| "To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months." | 3.66 | Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981) |
| "The hemodynamic effects of oral doses of prazosin and hydralazine were studied in the same group of patients with chronic congestive heart failure." | 3.66 | Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. ( Elkayam, U; Frishman, W; LeJemtel, T; Mathur, M; Sonnenblick, EH; Strom, J, 1981) |
| "In 10 patients with severe chronic congestive heart failure, changes in hemodynamic and cardiac performance at rest and during exercise were evaluated following short-term oral prazosin therapy." | 3.66 | Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure. ( Chatterjee, K; Parmley, WW; Ports, TA; Rubin, SA, 1981) |
| "Reviewed here are the data from 34 patients given prazosin for chronic intractable heart failure." | 3.66 | Prazosin and congestive heart failure: short- and long-term therapy. ( Burgess, JH; Rouleau, JL; Warnica, JW, 1981) |
| "The cardiocirculatory actions on the oral vasodilator prazosin were evaluated by cardiac catheterization, forearm plethysmography, echocardiography, treadmill exercise and symptoms in patients with advanced long-standing congestive heart failure." | 3.66 | Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective. ( Amsterdam, EE; Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1981) |
| "Central hemodynamic variables and regional blood flow and vascular resistances were ascertained in patients with severe congestive heart failure before and after the oral administration of prazosin hydrochloride or hydralazine." | 3.66 | Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. ( Bay, WH; Desch, CE; Leier, CV; Magorien, RD; Triffon, DW; Unverferth, DV, 1981) |
| "The effect of prazosin in congestive heart failure was assessed in 10 patients (age 39--69) years) with ischemic heart disease or cardiomyopathy in functional class II-IV (NYHA)." | 3.66 | Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure. ( Lund-Johansen, P; Ohm, OJ; von der Lippe, G, 1981) |
| "Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure." | 3.66 | Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981) |
| "To study the effect of prazosin therapy on left ventricular function in patients with chronic stable heart failure, first pass radionuclide angiography at rest and during exercise was performed in 15 patients before the administration of prazosin and after seven to 12 weeks of prazosin therapy." | 3.66 | Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. ( Cannon, PJ; Escala, E; Goldman, SA; Johnson, LL; Weiss, MB, 1980) |
| "The pharmacokinetics of prazosin (Minipress) were studied in nine patients with NYHA Class 3 or 4 congestive heart failure and in five healthy controls." | 3.66 | Altered prazosin pharmacokinetics in congestive heart failure. ( Arnold, S; Baughman, RA; Benet, LZ; Chatterjee, K; Lin, ET; Williams, RL, 1980) |
| "Prazosin improves hemodynamics promptly in patients with congestive heart failure (CHF), but tolerance to repeated doses may develop rapidly." | 3.66 | Effect of prazosin on renal function in congestive heart failure. ( Cohn, JN; Franciosa, JA; Pierpont, GL, 1980) |
| "To ascertain whether increased sympathetic nervous system activity may contribute to the attenuation of prazosin's effect on congestive heart failure, we measured plasma norepinephrine levels in 10 patients with severe heart failure before and after chronic prazosin therapy." | 3.66 | Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. ( Braunwald, E; Colucci, WS; Williams, GH, 1980) |
| " To determine whether this vasodilator elicits a positive inotropic response in the failing human ventricle, hydralazine, 75 or 100 mg, was administered orally to 14 patients with left ventricular dysfunction and congestive heart failure; the results were compared with those of first-dose prazosin at 5 and 10 mg." | 3.66 | Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. ( Boudoulas, H; Desch, CE; Leier, CV; Lewis, RP; Magorien, RD; Triffon, DW; Unverferth, DV, 1980) |
| "In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months." | 3.66 | [Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980) |
| "We evaluated the acute and chronic effects of prazosin treatment in 11 patients with chronic congestive heart failure, NYHA functional class III and IV." | 3.66 | Acute and chronic haemodynamic effects of prazosin in left ventricular failure. ( Foster, PR; Friedman, AW; McHenry, PL; Statza, J; Stein, L, 1981) |
| "The kinetics of oral prazosin was studied in 10 healthy normal subjects (NS) and in 9 patients with congestive heart failure (CHF)." | 3.66 | Influence of congestive heart failure on prazosin kinetics. ( Ball, R; Blaschke, T; Harrison, D; Jaillon, P; Kates, R; Rubin, P; Yee, YG, 1979) |
| "Four dogs with congestive heart failure associated with dirofilariasis and mitral valvular incompetence initially responded to treatment with digoxin or etamiphylline camsylate, and frusemide but became refractory to this therapy and were in cardiac decompensation." | 3.66 | The use of alpha blockade in the treatment of congestive heart failure associated with dirofilariasis and mitral valvular incompetence. ( Atwell, RB, 1979) |
| "To compare the hemodynamic effects of prazosin and nitroprusside in patients with severe congestive heart failure, nine patients with heart failure refractory to conventional therapy received oral prazosin and intravenous nitroprusside administered so as to produce a similar decrease in left ventricular filling pressure in each patient." | 3.66 | Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin. ( Gorlin, R; Herman, MV; Meller, J; Packer, M, 1979) |
| "A case of angina pectoris worsened by prazosin is presented." | 3.66 | Exacerbation of angina pectoris by prazosin. ( Charness, ME; Fishman, JA; Robertson, D, 1979) |
| "Of the vasodilators used at present in the treatment of heart failure, only nitroprusside and phentolamine inhibit platelet aggregation at therapeutic dose levels." | 3.66 | Influence of vasodilators used in the therapy of heart failure on platelet aggregation. ( Imhof, P; Pfister, B, 1979) |
| "The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure." | 3.66 | Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979) |
| "The hemodynamic effects of the new oral vasocilator prazosin were evaluated in 11 patients with congestive failure following myocardial infarction." | 3.66 | Use of oral prazosin hydrochloride in congestive failure following acute myocardial infarction. ( Coma-Canella, I; Jadraque, LM; Lombera, F; Lopez-Sendon, J, 1979) |
| " New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance." | 3.66 | Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979) |
| "Prazosin was administered orally at a maximal dose of 2 mg every 6 hours to 4 patients with congestive heart failure (CHF) who had not received either digitalis or diuretics for 72 hours before therapy." | 3.66 | Serial hemodynamic studies during the treatment of congestive heart failure with isolated low-dose oral prazosin therapy. ( Benchimol, A; Desser, KB; Reyns, PR; Romney, D, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 3.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 3.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "We compared cardiocirculatory actions of nitroprusside (NP) to prazosin (PZ) in eleven chronic coronary patients with refractory congestive heart failure." | 3.66 | Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. ( Awan, NA; Mason, DT; Miller, RR, 1978) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 3.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 3.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "To elucidate the hemodynamic effects of prazosin, an antihypertensive agent, in congestive heart failure, we studied 10 patients with ischemic cardiomyopathy and severe ventricular dysfunction." | 3.65 | Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. ( Awan, NA; Mason, DT; Maxwell, KS; Miller, RR, 1977) |
| "The dobutamine-induced increase in cardiac index remained virtually unchanged." | 2.67 | Preliminary evidence for the mechanism underlying the development of tolerance to prazosin in congestive heart failure: the alpha-agonistic properties of dobutamine unmasked by prazosin treatment. ( Giesen, G; Kersting, F; Kupp, M, 1993) |
| "Prazosin pre-treatment did not alter any of the renal responses to frusemide treatment (mean dose 85 +/- 14 mg)." | 2.67 | Renal effects of low dose prazosin in patients with congestive heart failure. ( Choy, AM; Lang, CC; Rahman, AR; Struthers, AD, 1993) |
| "Ventricular arrhythmia was a significant independent predictor in V-HeFT II but not in V-HeFT I." | 2.67 | Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F, 1993) |
| "Two groups of patients with congestive heart failure were studied, one with elevated (Group I) and another (Group II) with suppressed plasma concentrations of vasopressin." | 2.66 | Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. ( Bichet, DG; Kortas, C; Manzini, C; Marc-Aurèle, J; Mettauer, B; Rouleau, JL; Schrier, RW, 1986) |
| "Treatment with hydralazine-nitrate produced a 28% reduction in mortality compared with that in patients receiving placebo (95% confidence interval, 3% to 46%), whereas prazosin exerted no apparent beneficial effect." | 2.66 | Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1987) |
| "Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist." | 2.37 | Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. ( Eisen, G; Frishman, WH; Lapsker, J, 1988) |
| "Reduced mortality rates in congestive heart failure with vasodilator therapy has not been demonstrated, and prediction of clinical response to therapy is difficult." | 2.37 | Vasodilator therapy. ( Sutton, FJ, 1986) |
| " However, there are both clinical data and theoretic reasons to anticipate that some degree of tolerance may develop during the long-term use of most agents." | 2.36 | Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. ( Alexander, RW; Braunwald, E; Colucci, WS; Williams, GH, 1981) |
| "Effect of alpha-adrenergic blockers on pulmonary edema in lung transplantation was studied with a rat model of syngeneic left lung transplantation." | 1.30 | Alpha-adrenergic blockade in preventing posttransplant edema of lung allograft. ( Fujimura, S; Horikoshi, A; Kondo, T; Matsumura, Y; Okada, Y; Shimada, K, 1999) |
| "Prazosin had a 10-fold lower potency against epinephrine-induced contractions in the dorsal pedal artery, whereas it was not competitive against epinephrine in the saphenous vein." | 1.28 | Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. ( Armstrong, PW; Forster, C, 1990) |
| "Ten patients with congestive heart failure (class III and IV) underwent hemodynamic evaluation before and after a 5-mg oral dose of terazosin." | 1.28 | Rest and exercise cardiovascular effects of terazosin in congestive heart failure. ( Boudoulas, H; Leier, CV; Magorien, RD; Sinnathamby, S; Unverferth, DV, 1990) |
| "Therapy to decrease the load in congestive heart failure is now classified as acute and chronic vasodilator therapy." | 1.27 | Effect of prostacyclin and prazosin in the treatment of congestive heart failure; with special reference to the sympathetic nervous system. ( Kawai, C; Nakajima, H; Sakurai, T; Yui, Y, 1984) |
| "Patients with advanced congestive heart failure are high cost users of medical care, are limited by severe symptoms and have a poor prognosis." | 1.27 | [Current aspects of drug treatment of patients with congestive heart failure]. ( Bertel, O, 1983) |
| "Cardiac failure is usually defined according to clinical and haemodynamic criteria at rest although these patients are mainly symptomatic on effort." | 1.27 | [Value of an ergometric test for the assessment of cardiac failure]. ( Aubran, M; Camous, JP; Gibelin, P; Morand, P; Rainart, JP, 1984) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Prazosin is a post-synaptic alpha-blocker which acts on both cardiac preload and afterload." | 1.27 | [Prazosin in the treatment of chronic cardiac insufficiency]. ( Champoud, O; Cribier, A; Letac, B, 1985) |
| "Even though cardiac hypertrophy is viewed as a beneficial compensatory process that normalizes wall stress, the increased muscle mass carries with it the need of increased blood supply." | 1.27 | Effects of vasodilators on the coronary circulation in congestive heart failure. ( Burkart, F; Kiowski, W, 1988) |
| "Prazosin treatment produced an improvement in the hemodynamics which was associated with a decreased in the extracellular space, and intracellular K+, and an increase in the intracellular Ca++." | 1.27 | Effect of chronic prazosin treatment on the cardiac function and electrolytes in failing heart due to chronic mitral insufficiency. ( Bharadwaj, B; O'Neil, CL; Prasad, K, 1985) |
| "Isosorbide dinitrate was used in 16 patients, nitroglycerin in 36, pratsiol in 24, and captopryl in 20 patients." | 1.27 | [Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency]. ( Ageev, FT; Evdokimova, NKh; Mareev, VIu; Mukharliamov, NM; Novikov, SV, 1985) |
| "11 patients with congestive heart failure showed significant clinical and haemodynamic improvement after 4-week administration of 9 mg Prazosin/day." | 1.26 | [Alpha receptor blocking and cardial insufficiency]. ( Klein, W, 1982) |
| "Prazosin has proved to be beneficial in CHF resistant to digitalis and diuretics." | 1.26 | Haemodynamic effects of prazosin in CHF. ( Gale, EV; Kuan, P; Reuben, SR; Wilde, PM, 1981) |
| "Prazosin was used to test the acute response to changes in atrial receptors and hemofiltration to test the response to changes in volume receptors." | 1.26 | Antidiuretic hormone in congestive heart failure. ( Kochsiek, K; Liebau, G; Riegger, GA, 1982) |
| "With hydralazine there were parallel changes in the rate-pressure product and MVO2." | 1.26 | Vasodilators in heart failure secondary to coronary artery disease. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Twelve patients with congestive heart failure were monitored with invasive and noninvasive techniques to evaluate the effect of vasodilator treatment." | 1.26 | Effects of red rest and prazosin in congestive heart failure. ( Forfang, K; Ihlen, H; Kjekshus, J; Storstein, O; Thaulow, E, 1982) |
| "Modern management of congestive heart failure (CHF) employs inotropic drugs, vasodilators, and diuretics." | 1.26 | Problems in assessment of new pharmacologic agents for the heart failure patient. ( Benotti, JR; Braunwald, E; Carabello, BA; Colucci, WS; Grossman, W; Malacoff, R; Rude, RE; Wynne, J, 1981) |
| "Six patients with severe congestive heart failure were treated with nitroprusside intravenously." | 1.26 | Vasodilator therapy for congestive heart failure. ( Benzing, G; Dillon, TR; Janos, GG; Kaplan, S; Meyer, RA, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 266 (86.64) | 18.7374 |
| 1990's | 35 (11.40) | 18.2507 |
| 2000's | 5 (1.63) | 29.6817 |
| 2010's | 1 (0.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coutsos, M | 1 |
| Sala-Mercado, JA | 1 |
| Ichinose, M | 1 |
| Li, Z | 1 |
| Dawe, EJ | 1 |
| O'Leary, DS | 1 |
| Ajayi, AA | 5 |
| Sofowora, GG | 3 |
| Adigun, AQ | 2 |
| Asiyanbola, B | 2 |
| Ikram, H | 1 |
| Levine, TB | 2 |
| Hanley, SP | 1 |
| Cowley, A | 1 |
| Hampton, JR | 1 |
| Pohl, JE | 1 |
| Burden, AC | 1 |
| Colucci, WS | 7 |
| Holman, BL | 2 |
| Wynne, J | 3 |
| Carabello, B | 1 |
| Malacoff, R | 2 |
| Grossman, W | 2 |
| Braunwald, E | 7 |
| Kersting, F | 2 |
| Samosny, G | 1 |
| Kasper, W | 1 |
| Schuster, HP | 1 |
| Williams, GH | 3 |
| Hutton, I | 1 |
| Tweddel, AC | 1 |
| Bastian, BC | 1 |
| Murray, RG | 1 |
| Bühler, FR | 2 |
| Bolli, P | 1 |
| Hulthén, L | 1 |
| Amann, FW | 1 |
| Klein, W | 3 |
| Fischer, E | 1 |
| Siegenthaler, W | 1 |
| Taylor, SH | 2 |
| Silke, B | 1 |
| Kugler, J | 1 |
| Maskin, CS | 1 |
| Frishman, W | 2 |
| Sonnenblick, EH | 3 |
| LeJemtel, TH | 2 |
| Koller, H | 1 |
| Prager, H | 1 |
| Heinecker, R | 1 |
| Rubin, PC | 1 |
| Reid, JL | 1 |
| Shevchenko, VA | 1 |
| Kincaid-Smith, P | 1 |
| Mathey, DG | 1 |
| Bleifeld, W | 3 |
| Opie, LH | 1 |
| Ochs, HR | 1 |
| Bodem, G | 1 |
| Alexander, RW | 1 |
| Awan, NA | 15 |
| Beattie, JM | 1 |
| Evenson, ME | 1 |
| Needham, KE | 4 |
| Mason, DT | 21 |
| Joye, JA | 1 |
| Lee, G | 2 |
| DeMaria, AN | 4 |
| Amsterdam, EA | 3 |
| Ogasawara, B | 1 |
| Ogawa, K | 1 |
| Hayashi, H | 2 |
| Sassa, H | 2 |
| Evenson, MK | 3 |
| Chatterjee, K | 17 |
| Rouleau, JL | 7 |
| Parmley, WW | 10 |
| Sharpe, DN | 2 |
| Coxon, R | 2 |
| Stanaszek, WF | 1 |
| Kellerman, D | 1 |
| Brogden, RN | 1 |
| Romankiewicz, JA | 1 |
| Lui, HK | 1 |
| Packer, M | 8 |
| Medina, N | 4 |
| Yushak, M | 4 |
| Romankiewicz, N | 1 |
| Markham, RV | 1 |
| Corbett, JR | 1 |
| Gilmore, A | 1 |
| Pettinger, WA | 2 |
| Firth, BG | 1 |
| Froer, KL | 1 |
| Hall, D | 1 |
| Rudolph, W | 1 |
| Higginbotham, MB | 1 |
| Morris, KG | 1 |
| Bramlet, DA | 1 |
| Coleman, RE | 1 |
| Cobb, FR | 2 |
| Larbig, D | 2 |
| Nasse, H | 1 |
| Feldman, R | 1 |
| Beekman, RH | 1 |
| Rocchini, AP | 1 |
| Dick, M | 1 |
| Crowley, DC | 1 |
| Rosenthal, A | 1 |
| Yui, Y | 3 |
| Sakurai, T | 1 |
| Nakajima, H | 3 |
| Kawai, C | 3 |
| Szmydt, W | 1 |
| Kaftańska, A | 1 |
| Paradowski, S | 1 |
| Bertel, O | 5 |
| Satinsky, JD | 1 |
| Ciafone, RA | 1 |
| Gould, L | 3 |
| Gopalaswamy, C | 2 |
| Gibelin, P | 1 |
| Rainart, JP | 1 |
| Aubran, M | 1 |
| Camous, JP | 1 |
| Morand, P | 1 |
| Bolte, HD | 1 |
| Bussmann, WD | 7 |
| Antani, JA | 2 |
| Harrison, DC | 2 |
| Feldman, RC | 2 |
| Ball, RM | 2 |
| Netz, H | 1 |
| Hagel, KJ | 1 |
| Röhner, G | 1 |
| Rautenburg, HW | 1 |
| Shen, LH | 1 |
| Ku, FS | 1 |
| Liu, QS | 1 |
| Guzińska, B | 1 |
| Nartowicz, E | 1 |
| Berndt, H | 1 |
| Rumiński, W | 1 |
| Markiewicz, M | 1 |
| Przegaliński, J | 1 |
| Delius, W | 3 |
| Tomov, I | 2 |
| Kaloianova, A | 2 |
| Terzieva, L | 2 |
| Nikolov, G | 2 |
| Elenkova, A | 2 |
| Conti, CR | 6 |
| Mehta, J | 5 |
| Pepine, CJ | 3 |
| Nichols, WW | 1 |
| Goebel, R | 2 |
| Bassand, JP | 2 |
| Becque, O | 2 |
| Berthout, P | 2 |
| Vial, Y | 2 |
| Magnin, D | 1 |
| Bernard, Y | 1 |
| Maurat, JP | 2 |
| Sparvieri, F | 1 |
| Cesari, GP | 2 |
| Soro, A | 1 |
| Khomenko, VL | 1 |
| Pomerantsev, VP | 1 |
| Vasiuk, IuA | 1 |
| Cohn, JN | 18 |
| Franciosa, JA | 5 |
| Pierpont, G | 1 |
| Miles, D | 2 |
| Iacona, M | 3 |
| Mukharliamov, NM | 2 |
| Wagner, GC | 1 |
| Robinson, PH | 1 |
| Haq, A | 1 |
| Rakowski, H | 1 |
| Baigrie, R | 1 |
| McLaughlin, P | 1 |
| Burns, R | 1 |
| Tihal, H | 1 |
| Hilton, D | 1 |
| Feiglin, D | 1 |
| Mandell, HN | 1 |
| Deglin, SM | 1 |
| Champoud, O | 2 |
| Brunhes, G | 1 |
| Cribier, A | 2 |
| Pasquis, P | 1 |
| Letac, B | 2 |
| Chandy, F | 1 |
| Abdou, O | 1 |
| Rutishauser, W | 1 |
| Sánchez Domínguez, J | 3 |
| Largo, F | 1 |
| Barciela, R | 1 |
| Urbina, FJ | 1 |
| Villa, JG | 2 |
| Józan, M | 1 |
| Tarján, J | 1 |
| Tordasi, E | 1 |
| Wágner, G | 1 |
| Bordás, I | 1 |
| Jávor, A | 1 |
| Kovács, S | 1 |
| Hockings, BE | 1 |
| Cope, GD | 1 |
| Clarke, GM | 1 |
| Taylor, RR | 1 |
| Reuben, SR | 1 |
| Kuan, P | 1 |
| Gale, EV | 1 |
| Wilde, PM | 1 |
| Ihlen, H | 2 |
| Thaulow, E | 2 |
| Kjekshus, J | 2 |
| Forfang, K | 2 |
| Massie, BM | 2 |
| Gunnar, RM | 1 |
| Oba, M | 1 |
| Fukaya, T | 1 |
| Okubo, M | 1 |
| Niwa, T | 1 |
| Matsui, E | 1 |
| Stein, L | 2 |
| Henry, DP | 1 |
| Weinberger, MH | 1 |
| Taylor, CR | 1 |
| Baird, JR | 1 |
| Blackburn, KJ | 1 |
| Cambridge, D | 1 |
| Constantine, JW | 1 |
| Ghaly, MS | 1 |
| Hayden, ML | 1 |
| McIlhenny, HM | 1 |
| Moore, PF | 1 |
| Olukotun, AY | 1 |
| Pullman, LG | 1 |
| Salsburg, DS | 1 |
| Saxton, CA | 1 |
| Shevde, S | 1 |
| Benge, W | 1 |
| Hiramatsu, B | 1 |
| Serbin, VI | 1 |
| Gasanova, AS | 1 |
| Kluger, J | 1 |
| Cody, RJ | 1 |
| Laragh, JH | 1 |
| Engler, R | 1 |
| Pouleur, H | 1 |
| Link, J | 1 |
| Printz, M | 1 |
| Covell, JW | 1 |
| Riegger, GA | 2 |
| Liebau, G | 2 |
| Kochsiek, K | 3 |
| Kawashita, K | 1 |
| Yoshida, A | 1 |
| Labriola, S | 1 |
| Di Benedetto, S | 1 |
| Poggi, VM | 1 |
| Stern, L | 1 |
| Manfrin, M | 3 |
| Frascione, P | 1 |
| Budini, A | 1 |
| Colonna, PL | 1 |
| Schicchi, F | 1 |
| Chiesa, R | 1 |
| Storstein, O | 1 |
| Chokshi, AB | 1 |
| Patel, S | 1 |
| Gomes, GI | 1 |
| Burkart, F | 3 |
| Winchester, MA | 1 |
| Jaillon, P | 2 |
| Kates, RE | 1 |
| Elkayam, U | 3 |
| Mathur, M | 2 |
| LeJemtel, T | 1 |
| Strom, J | 2 |
| Rubin, SA | 4 |
| Ports, TA | 6 |
| Warnica, JW | 1 |
| Burgess, JH | 1 |
| Amsterdam, EE | 1 |
| Magorien, RD | 4 |
| Triffon, DW | 3 |
| Desch, CE | 3 |
| Bay, WH | 1 |
| Unverferth, DV | 6 |
| Leier, CV | 6 |
| González Villa, J | 1 |
| Urbina Fuentes, FJ | 2 |
| Menéndez Lozano, A | 2 |
| Kuhn, H | 1 |
| Boch, H | 1 |
| Lösse, B | 1 |
| Rude, RE | 1 |
| Benotti, JR | 1 |
| Carabello, BA | 1 |
| Arnold, S | 3 |
| Brundage, BH | 4 |
| Williams, RL | 3 |
| Ports, T | 1 |
| Chuck, L | 1 |
| Rouleau, J | 1 |
| Lemke, R | 2 |
| Trompler, A | 2 |
| Kaltenbach, M | 3 |
| Kleinman, Y | 1 |
| Tzivoni, D | 1 |
| López-Sendón, J | 3 |
| Coma Canella, I | 2 |
| Trongé, J | 1 |
| Villamayor, RM | 1 |
| Pérez Baliño, N | 1 |
| Riccitelli, MA | 1 |
| Bertolasi, CA | 2 |
| Pileggi, F | 1 |
| Bellotti, G | 1 |
| Galiano, N | 1 |
| de Moraes, V | 1 |
| Ramires, JA | 1 |
| de Mello, CP | 1 |
| Décourt, LV | 1 |
| Oliveri, R | 1 |
| Cremades, E | 1 |
| Bazzino, O | 1 |
| Doval, H | 1 |
| Sakurai, K | 1 |
| Wakabayashi, A | 1 |
| von der Lippe, G | 1 |
| Ohm, OJ | 1 |
| Lund-Johansen, P | 1 |
| Myers, JB | 1 |
| Morgan, TO | 1 |
| Walker, JN | 1 |
| Hauf, GF | 1 |
| Bubenheimer, P | 1 |
| Lönne, E | 1 |
| Roskamm, H | 1 |
| Honda, T | 1 |
| Hiramori, K | 1 |
| Haze, K | 1 |
| Saito, M | 1 |
| Fuseno, H | 1 |
| Fukami, K | 1 |
| Umemoto, M | 1 |
| Tanaka, N | 1 |
| Ikeda, M | 1 |
| Gronda, E | 2 |
| Mafrici, A | 1 |
| Ferrari, D | 1 |
| Cataldo, G | 1 |
| Salvadè, P | 1 |
| Pirelli, S | 1 |
| Mauri, F | 2 |
| Faletra, F | 1 |
| Carù, B | 1 |
| Hanrath, P | 2 |
| Kuck, KH | 2 |
| Mathey, D | 3 |
| Goldman, SA | 1 |
| Johnson, LL | 1 |
| Escala, E | 1 |
| Cannon, PJ | 1 |
| Weiss, MB | 1 |
| Atkins, FL | 1 |
| Segal, BL | 1 |
| Rubin, P | 2 |
| Blaschke, T | 2 |
| Dillon, TR | 1 |
| Janos, GG | 1 |
| Meyer, RA | 1 |
| Benzing, G | 1 |
| Kaplan, S | 1 |
| Greenberg, BH | 1 |
| Cabaniss, CD | 1 |
| Baughman, RA | 3 |
| Benet, LZ | 3 |
| Lin, ET | 2 |
| Pierpont, GL | 1 |
| Harper, RW | 1 |
| Claxton, H | 1 |
| Middlebrook, K | 1 |
| Anderson, S | 1 |
| Pitt, A | 1 |
| Mantle, JA | 1 |
| Russell, RO | 1 |
| Tauxe, WN | 1 |
| Dustan, HP | 1 |
| Rogers, WJ | 1 |
| Rackley, CE | 1 |
| Fitchett, DH | 1 |
| Pathé, M | 1 |
| Pardy, R | 1 |
| Despas, P | 1 |
| Hepp, A | 1 |
| Schick, KD | 1 |
| Haasis, R | 1 |
| Riegger, G | 1 |
| Bossi, M | 1 |
| Rovelli, F | 1 |
| Boudoulas, H | 2 |
| Lewis, RP | 1 |
| Franchi, F | 1 |
| Michelucci, A | 1 |
| Morace, G | 1 |
| Porciani, MC | 1 |
| Fantini, F | 1 |
| Wirtzfeld, A | 1 |
| Klein, G | 1 |
| Himmler, FC | 1 |
| Schmidt, G | 1 |
| Kutschera, I | 1 |
| Sauer, E | 1 |
| Zehnke, A | 1 |
| Foster, PR | 1 |
| Friedman, AW | 1 |
| Statza, J | 1 |
| McHenry, PL | 1 |
| García Puig, J | 1 |
| Gil Aguado, A | 1 |
| Arnalich, F | 1 |
| Gaspar, G | 1 |
| Anciones, B | 1 |
| Vázquez, JJ | 1 |
| Koshlia, VI | 1 |
| Maliukova, NG | 1 |
| Minatoguchi, S | 1 |
| Ito, H | 1 |
| Ishimura, K | 1 |
| Watanabe, H | 1 |
| Imai, Y | 1 |
| Koshiji, M | 1 |
| Asano, K | 1 |
| Hirakawa, S | 1 |
| Fujiwara, H | 1 |
| Kupp, M | 1 |
| Giesen, G | 1 |
| Zhu, J | 1 |
| Wang, D | 1 |
| Lu, Z | 1 |
| Liu, Z | 1 |
| Yang, D | 1 |
| Lang, CC | 1 |
| Choy, AM | 1 |
| Rahman, AR | 1 |
| Struthers, AD | 1 |
| Carson, PE | 2 |
| Johnson, GR | 3 |
| Dunkman, WB | 4 |
| Fletcher, RD | 1 |
| Farrell, L | 2 |
| Cintron, G | 2 |
| Johnson, G | 6 |
| Francis, G | 2 |
| Cobb, F | 1 |
| Hughes, CV | 1 |
| Wong, M | 2 |
| Goldman, S | 1 |
| Smith, R | 3 |
| Shabetai, R | 2 |
| Loeb, H | 1 |
| Tristani, F | 2 |
| Rector, T | 1 |
| Fletcher, R | 1 |
| Ziesche, S | 3 |
| Hughes, V | 1 |
| Bhat, G | 2 |
| Lopez, B | 1 |
| Loeb, HS | 1 |
| Henrick, A | 1 |
| Wilson, J | 1 |
| Cremo, R | 1 |
| Balogun, MO | 2 |
| Skomedal, T | 1 |
| Borthne, K | 1 |
| Aass, H | 1 |
| Geiran, O | 1 |
| Osnes, JB | 1 |
| Khaper, N | 1 |
| Singal, PK | 1 |
| Sofowora, G | 1 |
| Naidoo, DP | 1 |
| Rocke, A | 1 |
| Mitha, AS | 1 |
| Re, G | 1 |
| Bergamasco, L | 1 |
| Badino, P | 1 |
| Borgarelli, M | 1 |
| Odore, R | 1 |
| Tarducci, A | 1 |
| Zanatta, R | 1 |
| Girardi, C | 1 |
| Kaye, DM | 1 |
| Vaddadi, G | 1 |
| Gruskin, SL | 1 |
| Du, XJ | 1 |
| Esler, MD | 1 |
| Kondo, T | 1 |
| Horikoshi, A | 1 |
| Fujimura, S | 1 |
| Matsumura, Y | 1 |
| Okada, Y | 1 |
| Shimada, K | 1 |
| Meyer, GJ | 1 |
| Sterz, H | 1 |
| Enenkel, W | 1 |
| Massie, B | 1 |
| Rubin, S | 1 |
| Gelberg, H | 1 |
| Halawa, B | 1 |
| Brandt, D | 1 |
| Harpf, H | 1 |
| Lloyd, EA | 1 |
| Miller, RR | 7 |
| Aronow, WS | 2 |
| Danahy, DT | 1 |
| Meller, J | 3 |
| Lurie, M | 1 |
| Turbow, M | 1 |
| Whittaker, K | 1 |
| Van Camp, S | 1 |
| Hughes, D | 1 |
| Koch-Weser, J | 1 |
| Graham, RM | 1 |
| Awan, N | 1 |
| Prati, PL | 2 |
| Imhof, P | 2 |
| Gelberg, HJ | 1 |
| Yee, YG | 1 |
| Ball, R | 1 |
| Kates, R | 1 |
| Harrison, D | 1 |
| Atwell, RB | 1 |
| Gorlin, R | 2 |
| Herman, MV | 2 |
| Charness, ME | 1 |
| Fishman, JA | 1 |
| Robertson, D | 1 |
| Pfister, B | 1 |
| Ribner, HS | 1 |
| Frishman, WH | 2 |
| Arnold, SB | 1 |
| Coma-Canella, I | 1 |
| Lombera, F | 2 |
| Jadraque, LM | 1 |
| Martin Jadraque, L | 1 |
| Blanford, MF | 1 |
| Armstrong, PW | 2 |
| Reyns, PR | 1 |
| Romney, D | 1 |
| Desser, KB | 1 |
| Benchimol, A | 1 |
| Brundage, B | 1 |
| Parmley, W | 1 |
| Akamatsu, T | 1 |
| Suzuki, A | 1 |
| Yamamoto, T | 1 |
| Takahashi, S | 1 |
| Kimata, S | 1 |
| Hirosawa, K | 1 |
| Pezzella, A | 1 |
| Di Lorenzo, M | 1 |
| Barbis, V | 1 |
| Giovannini, E | 1 |
| Gambelli, G | 1 |
| Signoretti, P | 1 |
| Pittorino, L | 1 |
| Greco, C | 1 |
| Timio, M | 2 |
| Gentili, S | 2 |
| Schiaroli, M | 2 |
| Ronconi, M | 1 |
| Scandiffo, T | 1 |
| Veglia, L | 1 |
| Guerricchio, G | 1 |
| Straub, EJ | 1 |
| Feldman, RL | 1 |
| Laslett, LJ | 1 |
| Miller, MP | 1 |
| Specht, K | 1 |
| Vera, Z | 1 |
| Pede, S | 1 |
| Maxwell, K | 1 |
| Maxwell, KS | 2 |
| Neumann, A | 1 |
| Nishikimi, T | 1 |
| Uchino, K | 1 |
| Frohlich, ED | 1 |
| Osodi, OO | 1 |
| Akintomide, AO | 1 |
| DiBianco, R | 1 |
| Parker, JO | 1 |
| Chakko, S | 1 |
| Tanser, PH | 1 |
| Emmanuel, G | 1 |
| Singh, JB | 1 |
| Marlon, A | 1 |
| Forster, C | 1 |
| Antani, NJ | 1 |
| Nanivadekar, AS | 1 |
| Hasford, J | 2 |
| Koepcke, W | 1 |
| Lehmann, K | 2 |
| Weber, E | 2 |
| Sinnathamby, S | 1 |
| Köpcke, W | 1 |
| Assmann, I | 1 |
| Stone, CK | 3 |
| Imai, N | 3 |
| Sladek, CD | 2 |
| Liang, CS | 3 |
| Bjornson, DC | 1 |
| Rector, TS | 1 |
| Daniels, CE | 1 |
| Wertheimer, AI | 1 |
| Snowdon, DA | 1 |
| Litman, TJ | 1 |
| Riegger, AJ | 1 |
| Urbaszek, W | 2 |
| Graf, B | 2 |
| Sonders, RC | 1 |
| Patterson, SE | 1 |
| Huss, P | 1 |
| Parrish, D | 1 |
| Eisen, G | 1 |
| Lapsker, J | 1 |
| Sonoki, H | 1 |
| Uchida, Y | 1 |
| Tomaru, T | 1 |
| Sugimoto, T | 1 |
| Good, AP | 1 |
| Strauer, BE | 1 |
| Kiowski, W | 1 |
| Ruggie, N | 1 |
| Woolf, PD | 1 |
| Kawashima, S | 1 |
| Tuttle, RR | 1 |
| Artman, M | 1 |
| Graham, TP | 1 |
| Young, JB | 1 |
| Leon, CA | 1 |
| Pratt, CM | 1 |
| Le Pailleur, C | 1 |
| Aumont, MC | 1 |
| Cohen-Solal, A | 1 |
| Gourgon, R | 1 |
| Motté, G | 1 |
| Vacheron, A | 1 |
| Sakamoto, S | 1 |
| Hood, WB | 1 |
| Bölter, C | 1 |
| Zingler, C | 1 |
| Mekat, A | 1 |
| Nabel, HJ | 1 |
| Ernst, B | 1 |
| Todo, Y | 1 |
| Ohyanagi, M | 1 |
| Fujisue, R | 1 |
| Iwasaki, T | 1 |
| Burke, LJ | 1 |
| Rothlin, ME | 1 |
| Ol'binskaia, LI | 1 |
| Gofman, AM | 1 |
| Petrosian, IuR | 1 |
| Sutton, FJ | 1 |
| Mettauer, B | 2 |
| Bichet, D | 1 |
| Kortas, C | 2 |
| Manzini, C | 2 |
| Tremblay, G | 1 |
| Bayliss, J | 1 |
| Canepa-Anson, R | 1 |
| Norell, MS | 1 |
| Poole-Wilson, P | 1 |
| Sutton, G | 1 |
| Archibald, DG | 2 |
| Harston, WE | 2 |
| Tristani, FE | 2 |
| Jacobs, W | 2 |
| Francis, GS | 2 |
| Flohr, KH | 2 |
| Westheim, A | 1 |
| Koss, A | 1 |
| Sivertssen, E | 1 |
| Bichet, DG | 1 |
| Marc-Aurèle, J | 1 |
| Schrier, RW | 1 |
| Haeske, W | 1 |
| Kraus, C | 1 |
| Kromer, EP | 1 |
| Nikolić, V | 1 |
| Planinc, D | 1 |
| Rudar, M | 1 |
| Pagon, L | 1 |
| Prasad, K | 1 |
| O'Neil, CL | 1 |
| Bharadwaj, B | 1 |
| Chlewicka, I | 1 |
| Torbicki, A | 1 |
| Maciejewska, M | 1 |
| Friedman, WF | 1 |
| George, BL | 1 |
| Reifart, N | 1 |
| Schmidt-Moritz, AD | 1 |
| Nadj, M | 1 |
| Mareev, VIu | 1 |
| Novikov, SV | 1 |
| Evdokimova, NKh | 1 |
| Ageev, FT | 1 |
| Abrams, J | 1 |
| Fink, LI | 1 |
| Wilson, JR | 2 |
| Ferraro, N | 2 |
| Bucher, HJ | 1 |
| Ogawa, T | 1 |
| Sekiguchi, T | 1 |
| Ishii, M | 1 |
| Sugishita, Y | 1 |
| Ito, I | 1 |
| Wiener, DH | 1 |
| Pimentel Filho, WA | 1 |
| Ascer, E | 1 |
| Pontes, SC | 1 |
| Martins, LR | 1 |
| Braga, SL | 1 |
| Jorge, Sdo C | 1 |
| Pedreira, AC | 1 |
| Sousa, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Effect of Vasopressin on Kidney and Cardiac Function in Previously Hypertensive Patients With Septic Shock: A Randomized Clinical Trial[NCT06125184] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
37 reviews available for prazosin and Cardiac Failure
| Article | Year |
|---|---|
Current concepts in the treatment of congestive heart failure.
Topics: Calcium Channel Blockers; Captopril; Digitalis Glycosides; Dipeptides; Diuretics; Enalapril; Enzyme | 1984 |
Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure.
Topics: Drug Tolerance; Heart Failure; Hemodynamics; Hormones; Humans; Neurotransmitter Agents; Prazosin; Qu | 1981 |
[Beta and alpha-adrenoceptor blockers in the planning of anti-hypertensive therapy: recommendations for general practice].
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Biological Availability; | 1981 |
Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Child; Drug Tolerance; Heart Failure; H | 1982 |
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators].
Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Hea | 1983 |
Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Dr | 1981 |
Management of refractory congestive heart failure with prazosin.
Topics: Animals; Drug Evaluation; Drug Tolerance; Dyspnea; Echocardiography; Fatigue; Heart Failure; Hemodyn | 1981 |
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Hea | 1983 |
[Vasodilator agents in the treatment of cardiac insufficiency].
Topics: Captopril; Dihydralazine; Heart Failure; Humans; Hydralazine; Nitroglycerin; Nitroprusside; Phentola | 1984 |
[Treatment of heart failure with vasodilators].
Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests; | 1980 |
[Effect of vasodilator agents in chronic heart failure].
Topics: Cardiomegaly; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; P | 1981 |
Vasodilator therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri | 1980 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
Vasodilator therapy of congestive heart failure.
Topics: Aortic Valve Insufficiency; Captopril; Dobutamine; Heart Failure; Humans; Hydralazine; Isosorbide Di | 1980 |
Cardiovascular clinical pharmacology of impedance reducing agents.
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; Prazosin; | 1981 |
New approaches in the management of heart failure.
Topics: Aortic Valve Stenosis; Cardiac Output; Cardiography, Impedance; Cardiomyopathies; Cardiotonic Agents | 1980 |
The role of vasodilating agents in the treatment of chronic heart failure.
Topics: Cardiac Output; Chronic Disease; Dobutamine; Heart Failure; Humans; Muscle Contraction; Nitroprussid | 1980 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
[Peripheral vasodilators in the treatment of heart failure].
Topics: Cardiac Output; Cardiomyopathies; Coronary Circulation; Droperidol; Heart Failure; Humans; Hydralazi | 1982 |
Left ventricle and arteries: structure, function, hormones, and disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine Vasopressin; Dr | 2001 |
[New aspects in the treatment of acute cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Droperidol; Fent | 1978 |
[Cardiac therapy in the old patient].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Body Water; Calcium; Clonidine; Digitalis Glycos | 1979 |
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans | 1978 |
[Use of vasodilator agents in circulatory insufficienty].
Topics: Blood Circulation; Dihydralazine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitro | 1979 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Afterload reduction in the management of congestive heart failure following acute myocardial infarction.
Topics: Acute Disease; Dopamine; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Ni | 1978 |
Oral vasodilator therapy for chronic heart failure: a plea for caution.
Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin | 1978 |
Drug therapy. Prazosin.
Topics: Animals; Binding Sites; Dogs; Heart Failure; Humans; Hypertension; Prazosin; Quinazolines; Rats; Vas | 1979 |
[Vasodilator agents in the treatment of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitroprusside; P | 1978 |
[Treatment of cardiac failure with vasodilators (author's transl)].
Topics: Cardiac Glycosides; Diuretics; Drug Therapy, Combination; Heart Failure; Hydralazine; Hypotension; I | 1978 |
Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
Topics: Enalapril; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Surviva | 1991 |
[The extension of heart failure therapy with vasodilators].
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination; Heart | 1990 |
Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Heart Failure; Humans; Hypertension; Prazosin | 1988 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic | 1986 |
Potentially deleterious effects of long-term vasodilator therapy in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; M | 1987 |
Vasodilators for chronic congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Hydralaz | 1988 |
Vasodilator therapy.
Topics: Administration, Oral; Captopril; Cardiac Output; Dose-Response Relationship, Drug; Double-Blind Meth | 1986 |
58 trials available for prazosin and Cardiac Failure
| Article | Year |
|---|---|
Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
[Vasodilator therapy with alpha-receptor blockaders. Acute and chronic effect of prazosin and phentolamine in congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Adult; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Phentol | 1981 |
Comparison of the vasodilator prazosin and the selective beta1 agonist prenalterol on rest and exercise haemodynamics in CHF.
Topics: Adrenergic beta-Agonists; Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Hemodynamics; H | 1981 |
[Long-term drug treatment of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitroglyce | 1984 |
Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hemodynamics; Human | 1982 |
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Hea | 1983 |
Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Heart; Heart Failure; Humans; Ma | 1983 |
Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Double-Blind Method; Heart Fa | 1983 |
[Clinical and polycardiographic evaluation of prazosin in the treatment of chronic congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Heart Failure; Heart Function Tests; | 1984 |
[Effect of vasodilator agents in chronic heart failure].
Topics: Cardiomegaly; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; P | 1981 |
[Prazosin in arterial hypertension with cardiac insufficiency].
Topics: Adult; Aged; Cardiomegaly; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; | 1980 |
Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects.
Topics: Aged; Aldosterone; Blood Pressure; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Di | 1982 |
[Treatment of chronic congestive failure with vasodilators (acute trial with prazosin and erythrityl tetranitrate)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Clinical Trials as Topic; Erythrityl T | 1982 |
Long-term therapy of heart failure with prazosin: a randomized double blind trial.
Topics: Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Drug Toleranc | 1980 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
Prazosin in the treatment of severe chronic congestive cardiac failure.
Topics: Adult; Aged; Chronic Disease; Echocardiography; Follow-Up Studies; Heart Failure; Hemodynamics; Huma | 1980 |
Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure.
Topics: Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance; Epinephrine; Female; Heart Failure; | 1981 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.
Topics: Aged; Captopril; Coronary Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hu | 1982 |
[Vasodilator treatment of chronic heart failure: a chronic double-blind trial with prazosin and erythrityl tetranitrate].
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Erythrityl Tetranitrate; Female; Hea | 1981 |
[Treatment of congestive cardiac failure with vasodilators (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Dihydralazine; Heart Failure; Humans; Isosorbide Dinitr | 1981 |
[Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].
Topics: Adult; Aged; Dihydralazine; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; | 1980 |
Preliminary evidence for the mechanism underlying the development of tolerance to prazosin in congestive heart failure: the alpha-agonistic properties of dobutamine unmasked by prazosin treatment.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Dobutamine; Dose-Response Relationship, Drug; Drug Administr | 1993 |
Renal effects of low dose prazosin in patients with congestive heart failure.
Topics: Aged; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Kidney; M | 1993 |
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Topics: Atrial Fibrillation; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isoso | 1993 |
The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Age Factors; Aged; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorb | 1993 |
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Topics: Cause of Death; Death, Sudden, Cardiac; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; | 1993 |
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hyd | 1993 |
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Anaerobic Threshold; Drug Therapy, Combination; Enalapril; Exercise Test; Exercise Tolerance; Heart | 1993 |
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Echocardiography; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbi | 1993 |
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbid | 1993 |
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Cerebrovascular Disorders; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; | 1993 |
Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Angiotensin-Convert | 1996 |
Clinical implications of alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition 'cross talk' in heart failure in Nigerians.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Dru | 1996 |
Evaluation of ibopamine plus prazosin in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Deoxyepinephrine; Double-Blind Method; Drug | 1998 |
Reduced myocardial nerve growth factor expression in human and experimental heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Animals; Cells, Cultured; Down-Regulation; Heart Failure; Human | 2000 |
Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dou | 1978 |
Effect of prazosin vs placebo on chronic left ventricular heart failure.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Heart F | 1979 |
Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
Topics: Administration, Oral; Blood Pressure; Cardiac Output; Drug Evaluation; Drug Tolerance; Female; Heart | 1979 |
[Effect of prazosin in therapy-resistant chronic cardiac failure (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiac Volume; Female; Heart Failure; Heart Rate; Huma | 1979 |
Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Exercise; Female; Heart Failure; Hemod | 1991 |
First dose hypotension with enalapril and prazosin in congestive heart failure.
Topics: Aged; Drug Evaluation; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Hypotension; Log | 1991 |
Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
Topics: Aged; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Hypotension; Male; Prazosin | 1991 |
Statistical significance of Veterans Administration Vasodilator Heart Failure Trial results.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Research Design; Statistics as T | 1990 |
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance | 1986 |
Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Clonidine; Extremities; Female; Heart Failure; Hemodynamics; Humans; I | 1988 |
Role of vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Clinical Trials as Topic; Dipeptides; Double-Blind Method; Enalapril; Heart Failure; Huma | 1985 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide | 1988 |
Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity.
Topics: Captopril; Heart Failure; Hemodynamics; Humans; Prazosin; Renin; Time Factors; Vasopressins; Water-E | 1986 |
Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise.
Topics: Aged; Captopril; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Heart Failure | 1986 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Follow-Up Studies; Heart Failure | 1986 |
Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; | 1986 |
Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure.
Topics: Aged; Arginine Vasopressin; Blood Platelets; Captopril; Diuresis; Female; Glomerular Filtration Rate | 1986 |
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Heart Failure | 1987 |
[Minipress in congestive heart failure].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Age | 1985 |
[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Heart Va | 1985 |
216 other studies available for prazosin and Cardiac Failure
| Article | Year |
|---|---|
Muscle metaboreflex-induced coronary vasoconstriction limits ventricular contractility during dynamic exercise in heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Coronary Circulation; Coronary Vessels; Dogs; Hear | 2013 |
For the patient. New treatments for heart failure in Black people. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal re
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
The action of converting enzyme inhibitors in cardiac failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Humans; Prazosin; Renin-Angioten | 1984 |
Danger of withdrawal of vasodilator therapy in patients with chronic heart-failure.
Topics: Acute Disease; Aged; Drug Administration Schedule; Exercise Test; Female; Heart Failure; Heart Funct | 1980 |
Withdrawing vasodilators.
Topics: Heart Failure; Humans; Prazosin; Quinazolines; Substance Withdrawal Syndrome | 1980 |
Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Female; Heart Failure; Heart Ventricles; Humans; Lung; Male; Middle Ag | 1981 |
[Interamerican symposium: Prazosin in arterial hypertension and cardiac insufficiency. Acapulco, Mexico, September 2-3, 1979].
Topics: Congresses as Topic; Heart Failure; Hypertension; Mexico; Prazosin; Quinazolines | 1980 |
[Alpha receptor blocking and cardial insufficiency].
Topics: Adrenergic alpha-Antagonists; Cardiac Output; Catecholamines; Heart Failure; Humans; Prazosin; Strok | 1982 |
[Vasodilators in heart failure? Basic principles and its role in practice].
Topics: Adrenergic alpha-Antagonists; Captopril; Diazoxide; Furosemide; Heart Failure; Humans; Hydralazine; | 1981 |
The pharmacokinetic, pharmacodynamic and haemodynamic effects of acute and chronic alpha-adrenoceptor blockade in chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Digoxin; Female; Furosemide; Heart Failure; Hemodynamics; | 1981 |
Variable clinical response to long-term angiotensin inhibition in severe heart failure: demonstration of additive benefits of alpha-receptor blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cap | 1982 |
[The use of vasodilator agents in the therapy of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Calcium Channel Blockers; Captopril; Clonidine; Diuretics; Heart Failu | 1982 |
[Frequent errors in the therapy of heart disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biologic | 1982 |
Alpha-blockers and converting enzyme inhibitors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hu | 1983 |
Beta-adrenergic receptor blocking drugs in hypertension. With special reference to their use as initial therapy.
Topics: Adrenergic beta-Antagonists; Asthma; Central Nervous System; Depression, Chemical; Heart Failure; Hu | 1984 |
Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channe | 1984 |
[Alternatives to digitalis therapy?].
Topics: Albuterol; Captopril; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; | 1981 |
Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin.
Topics: Heart Failure; Hemodynamics; Humans; Muscle, Smooth, Vascular; Prazosin; Quinazolines; Receptors, Ad | 1982 |
Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cardiac Output; Chronic Disease; Diastole; H | 1980 |
Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin.
Topics: Adult; Aged; Cyclic AMP; Cyclic GMP; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; | 1981 |
Vasodilator therapy of severe congestive heart failure: the special importance of angiotensin-converting enzyme inhibition with captopril.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiac Catheterization; Echocardi | 1982 |
Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Heart Ventricles; Hemodynamics; | 1982 |
Effects of alpha-receptor blockade with prazosin in advanced chronic congestive heart failure.
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines; Receptors, Adrenergic, | 1983 |
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Topics: Adult; Aged; Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardioto | 1984 |
Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure.
Topics: Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Prazosin; Region | 1983 |
New approaches to managing congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Prazosin; Proline; Quinazolines | 1983 |
[Captopril in chronic congestive heart failure--dose-effect behavior and comparison with prazosin].
Topics: Adult; Aged; Captopril; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1983 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; | 1983 |
Chronic afterload reduction in the treatment of congestive heart failure.
Topics: Captopril; Drug Evaluation; Heart Failure; Humans; Hydralazine; Prazosin; Proline; Quinazolines | 1983 |
Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation.
Topics: Adolescent; Captopril; Cardiac Catheterization; Child; Child, Preschool; Digoxin; Heart Failure; Hea | 1984 |
Effect of prostacyclin and prazosin in the treatment of congestive heart failure; with special reference to the sympathetic nervous system.
Topics: Blood Pressure; Epoprostenol; Heart Failure; Hemodynamics; Humans; Infusions, Parenteral; Middle Age | 1984 |
Vasodilators for chronic congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Vasodilator Agents | 1984 |
[Current aspects of drug treatment of patients with congestive heart failure].
Topics: Blood Pressure; Digoxin; Diuretics; Heart Failure; Humans; Nitroglycerin; Prazosin; Vasodilator Agen | 1983 |
Chronic heart failure in the elderly: vasodilator therapy.
Topics: Aged; Blood Pressure; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine | 1983 |
Vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitro | 1983 |
Vasodilator drugs.
Topics: Calcium Channel Blockers; Captopril; Heart Failure; Humans; Hydralazine; Minoxidil; Nitroglycerin; N | 1984 |
[Value of an ergometric test for the assessment of cardiac failure].
Topics: Adult; Aged; Evaluation Studies as Topic; Exercise Test; Female; Heart Failure; Hemodynamics; Humans | 1984 |
[Sustained and beneficial hemodynamic effects of prazosin in cardiac insufficiency].
Topics: Blood Pressure; Cardiac Output; Cardiomegaly; Heart Failure; Hemodynamics; Humans; Prazosin; Pulmona | 1980 |
Prazosin for refractory cardiac failure in children.
Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Heart Failure; Humans; Infant; Male; Prazosin; | 1984 |
[Hemodynamic effects and clinical observations on prazosin in treating chronic refractory congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazos | 1984 |
[Effect of vasodilator treatment of chronic circulatory insufficiency on various polycardiographic parameters].
Topics: Chronic Disease; Drug Therapy, Combination; Female; Heart; Heart Failure; Heart Function Tests; Huma | 1983 |
[Prazosin (Adversuten)].
Topics: Blood Pressure; Chemical Phenomena; Chemistry; Heart Failure; Humans; Prazosin; Quinazolines; Vascul | 1983 |
[Hemodynamic effect of prazosin in patients with aortic and mitral valve insufficiency].
Topics: Adult; Aortic Valve Insufficiency; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; M | 1983 |
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
Topics: Adult; Aged; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitra | 1982 |
[Therapy of cardiac insufficiency: vasodilator agents].
Topics: Captopril; Heart Failure; Humans; Nitrates; Phentolamine; Prazosin; Vasodilator Agents | 1982 |
Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure.
Topics: Cardiac Output; Diuretics; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Contraction; | 1980 |
Use of vasodilators in congestive heart failure.
Topics: Cardiac Output; Cardiography, Impedance; Heart Failure; Hemodynamics; Humans; Long-Term Care; Prazos | 1980 |
[Effects of acute and chronic vasodilator administration on hemodynamics and catecholamine concentration in chronic left heart failure (author's transl)].
Topics: Blood Pressure; Cardiac Output; Cardiomyopathies; Catecholamines; Coronary Disease; Dopamine; Epinep | 1980 |
[Hemodynamic effects of prazosin in chronic congestive heart failure].
Topics: Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Qui | 1980 |
[Long-term therapy with oral prazosin in chronic congestive heart failure: a clinical and echocardiographic evaluation (author's transl)].
Topics: Adult; Echocardiography; Female; Heart Failure; Humans; Long-Term Care; Male; Middle Aged; Prazosin; | 1980 |
Long-term maintenance therapy with prazosin in congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Echocardiography; Heart Failure; Hear | 1981 |
[Peripheral vasodilators in the treatment of cardiac insufficiency].
Topics: Heart Failure; Humans; Infusions, Parenteral; Molsidomine; Morpholines; Nitroglycerin; Nitroprusside | 1981 |
The role of vasodilator therapy in the management of the patient with acute myocardial infarction.
Topics: Heart Failure; Heart Rupture; Hemodynamics; Humans; Hydralazine; Mitral Valve Insufficiency; Myocard | 1981 |
Vasodilator therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies.
Topics: Aged; Cardiac Output; Drug Evaluation; Echocardiography; Female; Heart Failure; Hemodynamics; Humans | 1982 |
Preload and afterload without anguish: a simplified framework.
Topics: Cardiac Output; Coronary Circulation; Heart Failure; Heart Function Tests; Humans; Hydralazine; Nitr | 1982 |
[Immediate and long-term effects of prazosin on hemodynamics in chronic cardiac insufficiency].
Topics: Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Quinazolines | 1982 |
Noninvasive assessment of left ventricular wall stress in chronic congestive heart failure patients.
Topics: Adult; Aged; Aortic Valve Insufficiency; Blood Pressure; Echocardiography; Female; Heart; Heart Fail | 1983 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
[Evaluation of prazosin in chronic cardiac insufficiency by external chronometry of the left ventricle].
Topics: Adult; Aged; Drug Evaluation; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Pr | 1983 |
[The effect of oral prazosin therapy on severe cardiac insufficiency].
Topics: Administration, Oral; Aged; Female; Heart Failure; Humans; Male; Middle Aged; Prazosin; Quinazolines | 1983 |
Management of refractory CHF with prazosin: importance of tolerance and tachyphylaxis.
Topics: Administration, Oral; Drug Tolerance; Echocardiography; Heart Failure; Hemodynamics; Humans; Myocard | 1981 |
Haemodynamic effects of prazosin in CHF.
Topics: Cardiac Catheterization; Cardiac Output; Digoxin; Drug Therapy, Combination; Furosemide; Heart Failu | 1981 |
Loss of prazosin effect in severe chronic CHF.
Topics: Adult; Aged; Bed Rest; Chronic Disease; Drug Tolerance; Echocardiography; Female; Heart Failure; Hem | 1981 |
Hydralazine in chronic CHF.
Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com | 1981 |
Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure.
Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Female; Heart Failure; Heart Rate; Hemo | 1980 |
The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril).
Topics: Aged; Captopril; Epinephrine; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepi | 1982 |
Changes in control of renin release in congestive heart failure in dogs: response to acute and chronic vasodilator therapy.
Topics: Animals; Blood Pressure; Blood Volume; Dogs; Heart Failure; Heart Rate; Hydralazine; Myocardial Infa | 1982 |
Antidiuretic hormone in congestive heart failure.
Topics: Adult; Edema; Heart Failure; Hemodynamics; Humans; Hyponatremia; Middle Aged; Osmolar Concentration; | 1982 |
Vasodilators in heart failure secondary to coronary artery disease.
Topics: Cardiac Output; Coronary Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Myocardi | 1982 |
Non-invasive radiocardiographic assessment of the effects of prazosin in congestive heart failure.
Topics: Adult; Blood Pressure; Cardiac Output; Electrocardiography; Female; Heart Failure; Heart Rate; Hemod | 1982 |
[Prazosin: clinical use in the treatment of arterial hypertension and cardiac insufficiency].
Topics: Heart Failure; Humans; Hypertension; Prazosin; Quinazolines | 1982 |
Congestive cardiomyopathy: therapeutic approach.
Topics: Administration, Oral; Blood Pressure; Cardiac Output; Cardiomyopathies; Cardiotonic Agents; Digoxin; | 1982 |
[Chronic use of vasodilators in the therapy of congestive cardiac insufficiency].
Topics: Drug Administration Schedule; Heart Failure; Heart Function Tests; Humans; Isosorbide Dinitrate; Pra | 1982 |
Effects of red rest and prazosin in congestive heart failure.
Topics: Adult; Aged; Bed Rest; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Qui | 1982 |
Prazosin therapy in congestive heart failure.
Topics: Administration, Oral; Heart Failure; Humans; Prazosin; Quinazolines | 1982 |
Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure.
Topics: Aged; Chronic Disease; Dizziness; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pr | 1981 |
Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Follow-Up Studies; Heart Failure; Heart Rate; Hemodynamics; Humans; | 1981 |
Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
Topics: Administration, Oral; Ambulatory Care; Chronic Disease; Drug Tolerance; Forearm; Heart Failure; Hemo | 1981 |
Oral vasodilator therapy with prazosin in severe congestive heart failure.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Chronic Disease; Heart Failure; Hemodynamics; | 1981 |
Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure.
Topics: Aged; Blood Pressure; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Male; Mi | 1981 |
Symposium on Congestive Heart Failure. Introduction.
Topics: Heart Failure; Humans; Prazosin; Quinazolines; Vasodilator Agents | 1981 |
Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure.
Topics: Administration, Oral; Heart; Heart Failure; Hemodynamics; Humans; Lactates; Myocardium; Oxygen Consu | 1981 |
Prazosin and congestive heart failure: short- and long-term therapy.
Topics: Aged; Diuretics; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Quinazoli | 1981 |
Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective.
Topics: Administration, Oral; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines; V | 1981 |
Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.
Topics: Cardiac Output; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Hydra | 1981 |
[Prazosin in heart insufficiency. Short-term hospital clinical trial].
Topics: Adult; Aged; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazos | 1981 |
[Chronic administration of prazosin in patients with congestive cardiomyopathy (author's transl)].
Topics: Adult; Chronic Disease; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle | 1981 |
Problems in assessment of new pharmacologic agents for the heart failure patient.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Cardiovascular Agents; Drug Evaluation; Energy Metabol | 1981 |
Hemodynamic effects of prazosin in chronic heart failure.
Topics: Adult; Aged; Animals; Cats; Drug Evaluation; Heart Failure; Hemodynamics; Humans; In Vitro Technique | 1981 |
Controlled study of long-term prazosin in refractory heart failure.
Topics: Acute Disease; Adult; Aged; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Mid | 1981 |
[Prazosin in the treatment of chronic resistant heart failure].
Topics: Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines | 1981 |
[Prazosin in chronic refractory cardiac insufficiency: results of continuous long-term therapy].
Topics: Adult; Aged; Drug Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Prazosin; Prospective | 1981 |
[Comparative hemodynamic effect of sodium nitroprusside and prazosin hydrochloride in patients with cardiac insufficiency following acute myocardial infarction].
Topics: Aged; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infa | 1981 |
[Vasodilator therapy of pump failure in acute myocardial infarction].
Topics: Adult; Aged; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; Male; | 1980 |
[Usefulness of vasodilators in congestive cardiac insufficiency: studies with prazosin].
Topics: Adult; Aged; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Nit | 1980 |
[Echocardiographic, hemodynamic and clinical effects of prazosin in subjects with severe cardiopathy caused by Chagas disease].
Topics: Adult; Chagas Cardiomyopathy; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Middle Ag | 1980 |
[Acute myocardial infarction with pump failure: hemodynamic response to prazosin].
Topics: Adult; Aged; Arterioles; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial | 1980 |
[Alterations in the sympathetic nervous activity during vasodilator therapy by nitroprusside and prazosin in patients with congestive heart failure (author's transl)].
Topics: Adult; Aged; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nitropru | 1981 |
Acute hemodynamic and long-term clinical effects of prazosin in the treatment of chronic congestive heart failure.
Topics: Adult; Aged; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; | 1981 |
Effect of prazosin on renal function in chronic congestive cardiac failure.
Topics: Adult; Aged; Body Weight; Creatinine; Gout; Heart Failure; Humans; Kidney; Male; Middle Aged; Prazos | 1981 |
[The effects of prazosin in patients with chronic refractory heart failure-acute hemodynamic effects of oral prazosin and long-term therapy (author's transl)].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Mal | 1981 |
[Limitations of long-term treatment with vasodilator agents in increasing maximum functional capacity in patients with left ventricular insufficiency].
Topics: Exercise Test; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Male; Middle Aged | 1981 |
[Long-term results of vasodilator therapy with prazosin in severe refractory cardiac insufficiency].
Topics: Capillary Resistance; Heart Failure; Humans; Prazosin; Quinazolines; Time Factors | 1981 |
[Acute and chronic treatment of chronic cardiac insufficiency with nitrates or prazosin respectively].
Topics: Acute Disease; Chronic Disease; Heart Failure; Humans; Nitrates; Prazosin; Quinazolines | 1981 |
[Permanent therapy of chronic cardiac insufficiency with prazosin].
Topics: Adult; Erectile Dysfunction; Female; Heart Failure; Humans; Hypotension, Orthostatic; Male; Middle A | 1981 |
Vasodilator therapy in congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Myocardial Infarction; Prazosin; Quinazolines; Vasodilator Agen | 1981 |
Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate; Humans; Male; Middle | 1980 |
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Phentolamine; Prazosin; Vasodilator Agents | 1980 |
New therapies in the management of congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine; Prazosin; Quinazolines | 1980 |
New approaches to therapy of acute heart failure.
Topics: Antihypertensive Agents; Dobutamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroprusside; Ox | 1980 |
Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.
Topics: Adult; Aged; Cardiac Output; Energy Metabolism; Heart Failure; Hemodynamics; Humans; Hydralazine; La | 1980 |
Prazosin protein binding in health and disease.
Topics: Adult; Blood Proteins; Erythrocytes; Female; Heart Failure; Humans; In Vitro Techniques; Kidney Fail | 1980 |
Vasodilator therapy for congestive heart failure.
Topics: Adolescent; Adult; Child; Child, Preschool; Digoxin; Diuretics; Drug Therapy, Combination; Ferricyan | 1980 |
Beneficial effects of afterload reduction therapy in patients with congestive heart failure and moderate aortic stenosis.
Topics: Adult; Aged; Aortic Valve Stenosis; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rat | 1980 |
Vasodilator therapy of chronic congestive heart failure.
Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin | 1980 |
Long-term therapy with prazosin in severe chronic congestive heart failure.
Topics: Blood Pressure; Capillary Resistance; Dyspnea; Heart Failure; Heart Rate; Humans; Prazosin; Quinazol | 1980 |
Altered prazosin pharmacokinetics in congestive heart failure.
Topics: Adult; Aged; Female; Heart Failure; Humans; Kidney Diseases; Kinetics; Liver; Male; Metabolic Cleara | 1980 |
Effect of prazosin on renal function in congestive heart failure.
Topics: Aged; Blood Pressure; Creatinine; Diuresis; Heart Failure; Humans; Kidney; Male; Middle Aged; Prazos | 1980 |
Heart rate response to oral prazosin in patients with chronic congestive heart failure.
Topics: Heart Failure; Heart Rate; Humans; Prazosin; Quinazolines | 1980 |
High-performance liquid chromatographic determination of prazosin in human plasma, whole blood and urine.
Topics: Chromatography, High Pressure Liquid; Heart Failure; Humans; Kinetics; Prazosin; Quinazolines | 1980 |
The acute and chronic haemodynamic effects of prazosin in severe congestive cardiac failure.
Topics: Blood Pressure; Cardiac Output; Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines; Vascula | 1980 |
Effects of vasodilators on renal function in severe heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart Failure; Humans; Isosorbide Dinitrate; Kidney; Mi | 1980 |
Effect of vasodilator drugs on exercise performance in cardiac failure. Comparison of hydralazine and prazosin.
Topics: Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Oxygen Con | 1980 |
Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure.
Topics: Heart Failure; Humans; Norepinephrine; Posture; Prazosin; Quinazolines; Sympathetic Nervous System; | 1980 |
[Variable acute effects of prazosin on left ventricular failure (author's transl)].
Topics: Adult; Arterioles; Blood Pressure; Cardiac Catheterization; Female; Heart Failure; Heart Ventricles; | 1980 |
[Vasodilator therapy of congestive heart failure: comparison of hemodynamic effects after administration of nitroprusside i.v. and oral prazosin (author's transl)].
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Ferricyanides; Heart; Heart Failure; Hemodynamic | 1980 |
Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure.
Topics: Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Humans; Hydralazine; Myocardial Contrac | 1980 |
[Evaluation of long-term treatment with isosorbide dinitrate and prazosin in cardiac insufficiency].
Topics: Adult; Aged; Digoxin; Drug Evaluation; Female; Furosemide; Heart Failure; Heart Rate; Hemodynamics; | 1980 |
[Prazosin long-term treatment in severe chronic cardiac failure (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Digitalis Glycosides; Diuretics; Drug | 1980 |
Acute and chronic haemodynamic effects of prazosin in left ventricular failure.
Topics: Aged; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Q | 1981 |
[Treatment of cardiac insufficiency with systemic vasodilator agents].
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrites; Nitroprusside; Prazosin; Vasodilator Age | 1980 |
[Changes in external respiration due to vasoactive therapy in patients with heart failure].
Topics: Adult; Aged; Female; Heart Failure; Humans; Lung; Male; Middle Aged; Nitroglycerin; Pentoxifylline; | 1995 |
Modulation of noradrenaline release through presynaptic alpha 2-adrenoceptors in congestive heart failure.
Topics: Aged; Epinephrine; Feedback; Heart Failure; Humans; Middle Aged; Nitroglycerin; Norepinephrine; Phen | 1995 |
Hemodynamic effects of terazosin in congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; | 1993 |
Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle.
Topics: Adrenergic Antagonists; Heart; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Myocard | 1997 |
Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats.
Topics: Animals; Captopril; Catalase; Glutathione Peroxidase; Heart; Heart Failure; Hemodynamics; Lipid Pero | 1997 |
Canine dilated cardiomyopathy: lymphocyte and cardiac alpha(1)- and beta-adrenoceptor concentrations in normal and affected great danes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomyopathy, Dilated; Catecho | 1999 |
Alpha-adrenergic blockade in preventing posttransplant edema of lung allograft.
Topics: Adrenergic alpha-Antagonists; Animals; Drug Evaluation, Preclinical; Heart Failure; Hemodynamics; Is | 1999 |
[Sublingual captopril: indications and advantages?].
Topics: Administration, Oral; Administration, Sublingual; Adrenergic alpha-Antagonists; Angiotensin-Converti | 2000 |
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
Afterload reduction in the treatment of cardiac failure.
Topics: Blood Pressure; Heart Failure; Humans; Hydralazine; Nitroglycerin; Nitroprusside; Phentolamine; Praz | 1978 |
[Vasodilator therapy of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Prazosin; Stroke Volume; | 1979 |
Nonparenteral vasodilator therapy for chronic congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglycerin; Prazosin; Vasodilator Age | 1979 |
[Progress in the therapy of acute and chronic cardiac insufficiency by means of systemic vasodilators. Studies with prazosin and nitroglycerin].
Topics: Blood Pressure; Catecholamines; Heart Failure; Heart Ventricles; Humans; Nitroglycerin; Prazosin; Qu | 1979 |
Afterload reduction in congestive heart failure.
Topics: Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; | 1978 |
Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Ma | 1979 |
Influence of congestive heart failure on prazosin kinetics.
Topics: Administration, Oral; Adult; Aged; Female; Half-Life; Heart Failure; Humans; Kinetics; Male; Middle | 1979 |
The use of alpha blockade in the treatment of congestive heart failure associated with dirofilariasis and mitral valvular incompetence.
Topics: Animals; Digoxin; Dirofilariasis; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitra | 1979 |
Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.
Topics: Administration, Oral; Aged; Female; Ferricyanides; Heart Failure; Heart Rate; Hemodynamics; Humans; | 1979 |
Exacerbation of angina pectoris by prazosin.
Topics: Acute Disease; Aged; Angina Pectoris; Blood Pressure; Heart Failure; Humans; Hypertension; Male; Pra | 1979 |
Influence of vasodilators used in the therapy of heart failure on platelet aggregation.
Topics: Dihydralazine; Heart Failure; Humans; Hydralazine; In Vitro Techniques; Phentolamine; Platelet Aggre | 1979 |
Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Dose-Response Re | 1979 |
Attenuation of prazosin effect on cardiac output in chronic heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Drug Administration Schedule; Female; | 1979 |
Use of oral prazosin hydrochloride in congestive failure following acute myocardial infarction.
Topics: Acute Disease; Aged; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate; Humans; Male | 1979 |
[Hemodynamic effect of prazosin in congestive cardiac insufficiency of acute degree].
Topics: Acute Disease; Adolescent; Adult; Child; Heart Failure; Hemodynamics; Humans; Middle Aged; Prazosin; | 1979 |
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni | 1979 |
Serial hemodynamic studies during the treatment of congestive heart failure with isolated low-dose oral prazosin therapy.
Topics: Administration, Oral; Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosi | 1979 |
[Hemodynamic effects of prazosin in heart failure].
Topics: Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines | 1979 |
Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1979 |
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Ferricyanides; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; | 1979 |
[Vasodilator therapy with prazosin for severe congestive heart failure--hemodynamic effects of oral single administration and chronic use (author's transl)].
Topics: Administration, Oral; Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosi | 1979 |
[Premises on the use of vasodilator agents. The venous or mixed vasodilators].
Topics: Heart Failure; Humans; Isosorbide Dinitrate; Prazosin; Vasodilator Agents | 1979 |
[Efficacy of prazosin in severe cardiac insufficiency].
Topics: Adult; Aged; Blood Pressure; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Kinetocar | 1979 |
[Echocardiographic changes in severe congestive heart failure treated with prazosin].
Topics: Aged; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Failure; Humans; Male; | 1979 |
Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure.
Topics: Adult; Aged; Blood Circulation; Coronary Disease; Female; Ferricyanides; Heart Failure; Heart Rate; | 1978 |
Clinical use of prazosin in chf.
Topics: Heart Failure; Humans; Prazosin; Quinazolines | 1978 |
Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure.
Topics: Administration, Oral; Adult; Blood Pressure; Cardiac Output; Drug Evaluation; Ferricyanides; Heart F | 1978 |
Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
Topics: Aged; Coronary Disease; Digitalis Glycosides; Female; Furosemide; Heart Failure; Humans; Hydralazine | 1978 |
Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output.
Topics: Acute Disease; Arteries; Cardiac Output; Chronic Disease; Electrocardiography; Forearm; Heart Failur | 1978 |
Vasodilator and inotropic therapy of heart failure [panel discussion].
Topics: Animals; Cardiac Output; Coronary Circulation; Dobutamine; Dogs; Dose-Response Relationship, Drug; H | 1978 |
Use of vasodilator drugs in congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroprusside; Prazosin; Vasodilator Agent | 1978 |
[Prazosin in refractory congestive heart failure].
Topics: Adult; Aged; Coronary Disease; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Male; Middle | 1978 |
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
Topics: Aged; Chronic Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Middle | 1979 |
Effects of prazosin on forearm resistance and capacitance vessels.
Topics: Adult; Aged; Blood Pressure; Female; Forearm; Heart Failure; Heart Rate; Humans; Male; Middle Aged; | 1977 |
Vasodilator therapy--a physiologic approach to the treatment of heart failure.
Topics: Administration, Oral; Advertising; Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Q | 1977 |
Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Blood Pressure; Cardiac Output; Chronic Disease; | 1977 |
Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.
Topics: Blood Pressure; Cardiac Output; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Male | 1977 |
Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats.
Topics: Adrenergic alpha-Antagonists; Animals; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidn | 1992 |
The influence of captopril on intrahospital mortality and duration of hospitalization in Nigerians with congestive heart failure.
Topics: Captopril; Digoxin; Diuretics; Drug Therapy, Combination; Heart Failure; Hospital Mortality; Hospita | 1992 |
Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes.
Topics: Animals; Azepines; Blood Pressure; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Dru | 1990 |
Prazosin in chronic congestive heart failure due to ischemic heart disease.
Topics: Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up | 1991 |
Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Coronary Circulation; Exercise; Female; Heart Failure; Hemodynamics; H | 1990 |
Attenuation of pressor responses to arginine vasopressin in right-sided congestive heart failure.
Topics: Animals; Aorta; Arginine Vasopressin; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Heart | 1990 |
Impact of a drug-use review program intervention on prescribing after publication of a randomized clinical trial.
Topics: Attitude of Health Personnel; Drug Prescriptions; Drug Utilization; Heart Failure; Hospitals, Vetera | 1990 |
[Prazosin in the treatment of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output; Chronic Disease; Heart Failure; Humans; Mi | 1985 |
Neurohumoral vasoconstrictor systems in heart failure.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Captopril; Cardiac Output; Dogs; Heart; Heart Failure | 1985 |
[Therapy of chronic heart failure with vasodilators].
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captop | 1986 |
Pharmacokinetics of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Blood Proteins; Chemical Phenomen | 1986 |
The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Exercise Test; Female; | 1986 |
[Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs].
Topics: Adrenergic alpha-Antagonists; Animals; Disease Models, Animal; Dobutamine; Dogs; Heart Failure; Hemo | 1988 |
[Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects].
Topics: Blood Pressure; Cardiac Volume; Cardiomegaly; Cardiomyopathy, Hypertrophic; Clonidine; Coronary Circ | 1985 |
Effects of vasodilators on the coronary circulation in congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiomegaly; Cilazapri | 1988 |
Current indications for vasodilator therapy for left ventricular failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hu | 1985 |
The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs.
Topics: Adrenocorticotropic Hormone; Animals; beta-Endorphin; Dogs; Endorphins; Heart Failure; Hemodynamics; | 1987 |
Guidelines for vasodilator therapy of congestive heart failure in infants and children.
Topics: Captopril; Child; Child, Preschool; Enalapril; Heart Diseases; Heart Failure; Heart Ventricles; Hemo | 1987 |
[Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Male | 1987 |
Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure.
Topics: Animals; Arginine Vasopressin; Cardiac Output; Chronic Disease; Dogs; Epinephrine; Heart Failure; He | 1988 |
[The status of prazosin in therapy of chronic heart failure].
Topics: Cardiomyopathy, Dilated; Coronary Disease; Drug Therapy, Combination; Heart Failure; Heart Valve Dis | 1988 |
Radionuclear measurement of peripheral hemodynamics in selection of vasodilators for treatment of heart failure.
Topics: Aged; Arm; Blood Flow Velocity; Blood Volume; Female; Heart Failure; Humans; Isosorbide Dinitrate; M | 1988 |
Uncovering the cause of orthostatic hypotension.
Topics: Heart Failure; Humans; Hypotension, Orthostatic; Nursing Assessment; Prazosin | 1988 |
[Current management of left heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Catecholamines; Digitalis Glycoside | 1987 |
[Prazosin pharmacodynamics and pharmacokinetics in patients with myocardial infarct complicated by heart failure in the subacute period].
Topics: Adult; Aged; Cardiac Catheterization; Drug Tolerance; Electrocardiography; Female; Half-Life; Heart | 1987 |
[Prazosin in the treatment of chronic heart failure].
Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Prazosin | 1986 |
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Captopril; Cardiomyopathy, Dilated; Coronary Disease; Female; Heart Failure; Hemodynami | 1986 |
Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment.
Topics: Adult; Captopril; Diuretics; Drug Therapy, Combination; Drug Tolerance; Edema; Female; Heart Failure | 1987 |
Can prazosin be used in the treatment of refractory heart failure only on the basis of clinical monitoring?
Topics: Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Electrocardiography; Female; Heart | 1987 |
Vasodilator therapy in congestive heart failure.
Topics: Heart Failure; Humans; Isosorbide Dinitrate; Prazosin; Random Allocation | 1986 |
Effect of chronic prazosin treatment on the cardiac function and electrolytes in failing heart due to chronic mitral insufficiency.
Topics: Animals; Calcium; Dogs; Female; Heart Failure; Hemodynamics; Male; Mitral Valve Insufficiency; Myoca | 1985 |
Treatment of congestive heart failure by altering loading conditions of the heart.
Topics: Captopril; Cardiac Output; Child; Digoxin; Dopamine; Drug Therapy, Combination; Heart; Heart Failure | 1985 |
[Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency].
Topics: Administration, Oral; Adolescent; Adult; Captopril; Chronic Disease; Female; Heart Failure; Hemodyna | 1985 |
Vasodilator therapy for chronic congestive heart failure.
Topics: Captopril; Cardiac Catheterization; Heart Failure; Hospitalization; Humans; Hydralazine; Myocardial | 1985 |
Exercise ventilation and pulmonary artery wedge pressure in chronic stable congestive heart failure.
Topics: Cardiac Output; Dobutamine; Exercise Test; Heart Failure; Humans; Male; Middle Aged; Physical Exerti | 1986 |
[Vasodilators in chronic heart insufficiency].
Topics: Calcium Channel Blockers; Dihydralazine; Heart Failure; Humans; Isosorbide Dinitrate; Prazosin; Vaso | 1986 |
[Correlations between resting hemodynamics and exercise tolerance before and after prazosin therapy in patients with chronic congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Midd | 1985 |
Effect of the sympathetic nervous system on limb circulation and metabolism during exercise in patients with heart failure.
Topics: Aged; Cardiac Output; Heart Failure; Humans; Lactates; Lactic Acid; Leg; Male; Middle Aged; Oxygen C | 1985 |
[Clinical, echocardiographic and radioisotopic evaluation of the effect of prazosin on left ventricular function in patients with congestive heart failure refractory to conventional therapy].
Topics: Adolescent; Adult; Aged; Echocardiography; Female; Heart; Heart Failure; Heart Ventricles; Humans; M | 1985 |